




(72) TANG, Y. TOM, US
(72) LAL, PREETI, US
(72) BANDMAN, OLGA, US
(72) YUE, HENRY, US
(72) CORLEY, NEIL C., US
(72) GUEGLER, KARL J., US
(72) GORGONE, GINA A., US
(72) BAUGHN, MARIAH R., US
(72) PATTERSON, CHANDRA, US
(71) INCYTE PHARMACEUTICALS, INC., US
(51) Int.Cl.⁷ C12N 15/12, C12Q 1/68, C07K 14/47, C07K 16/18,
A61K 38/17
(30) 1998/08/27 (60/098,206) US
(54) **MOLECULES ASSOCIEES AU TRANSPORT DE PROTEINES**
(54) **PROTEIN TRANSPORT-ASSOCIATED MOLECULES**

(57) The invention provides human protein transport molecules (PTAM) and polynucleotides which identify and encode PTAM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PTAM.

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12Q 1/68, A61K 38/17, C07K 16/18	A2	(11) International Publication Number: WO 00/12703 (43) International Publication Date: 9 March 2000 (09.03.00)
(21) International Application Number: PCT/US99/19616 (22) International Filing Date: 26 August 1999 (26.08.99) (30) Priority Data: 60/098,206 27 August 1998 (27.08.98) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 60/098,206 (CIP) Filed on 27 August 1998 (27.08.98) (71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TANG, Y., Tom [US/US]; 4230 Ranwick Court, San Jose, CA 95118 (US). LAL, Preeti [IN/US]; 2382 Lass Drive, Santa Clara, CA 95054 (US). BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). YUE, Henry [US/US]; 826 Lois Avenue, Sunnyvale, CA 94087 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue, #30, Sunnyvale, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Av-		enue, Menlo Park, CA 94025 (US). GORGONE, Gina, A. [US/US]; 1253 Pinecrest Drive, Boulder Creek, CA 95006 (US). BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). PATTERSON, Chandra [US/US]; 490 Sherwood Way #1, Menlo Park, CA 94087 (US). (74) Agents: BILLINGS, Lucy et al.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: PROTEIN TRANSPORT-ASSOCIATED MOLECULES		
(57) Abstract The invention provides human protein transport molecules (PTAM) and polynucleotides which identify and encode PTAM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of PTAM.		

PROTEIN TRANSPORT-ASSOCIATED MOLECULES

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of protein transport-associated molecules and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative and secretory disorders.

BACKGROUND OF THE INVENTION

10 The organization of a cell is designed for optimal structure and function. Each molecule produced by the cell must be targeted to the appropriate subcellular location. To be properly localized, each molecule must contain information which provides its cellular address. Trafficking machinery can use this information to appropriately transport the molecule to its destination. This is a dynamic process, and the location of a molecule can change over time. Defects in any step
15 involving a molecule's proper localization can result in a disorder, such as diabetes or Alzheimer's disease. (James, D.E., and Piper, R.C. (1994) J. Cell Biol. 126:1123-1126; and Nordstedt, C., et al. (1993) J. Biol. Chem. 268:608-612.)

The information that provides the address for targeting resides within the primary structure of the protein. Certain amino acid sequences act as "delivery codes" during the
20 processing or recycling of a molecule and assure that the molecule is properly localized. Several motifs have been identified. The two principal motifs are the nuclear localization signal and signal peptide. Nuclear localization signals (NLS) consist of short stretches of amino acids enriched in basic residues. NLS are found on proteins that are targeted to the nucleus, such as the glucocorticoid receptor. The NLS is recognized by the NLS receptor, importin, which then
25 interacts with the monomeric GTP-binding protein Ran. This NLS protein/receptor/Ran complex navigates the nuclear pore with the help of the homodimeric protein nuclear transport factor 2 (NTF2). NTF2 binds to the GDP-bound form of Ran and to multiple proteins of the nuclear pore complex, such as p62.

Signal peptides are found on proteins that are targeted to the endoplasmic reticulum (ER).
30 Signal peptides consist of stretches of amino acids enriched in hydrophobic residues. Signal peptides are usually found at the extreme N-terminus of the protein and are recognized by a cytosolic signal-recognition peptide (SRP). The SRP binds to the signal peptide and to an SRP receptor, an integral membrane protein in the ER. Once bound to the SRP receptor, the newly formed protein containing the signal peptide is translocated across the ER membrane. Proteins

WO 00/12703

PCT/US99/19616

containing signal peptides may end up inserted into the lipid bilayer, or they may end up in the lumen of an organelle or secreted from the cell.

Proteins may also contain separate motifs that specify delivery or retention in a subcellular location. For example, the trans-Golgi network integral membrane protein TGN38 cycles between
 5 the trans-Golgi network (TGN) and the plasma membrane. TGN38 contains two separate motifs. One motif, located within the cytoplasmic tail, is responsible for delivery to the Golgi. A second motif, located within the hydrophobic membrane-spanning region, is responsible for retention of the protein in the TGN. (Stephens, D.J., et al. (1997) J. Biol. Chem. 272:14104-14109.)
 Modification of the motif may alter the address for a protein and cause it to be relocated. For
 10 example, plasma membrane receptors, such as the epidermal growth factor (EGF) receptor and the T-cell receptor (TCR), contain targeting motifs which, when ligand binds to the receptor, become phosphorylated. Phosphorylation of the targeting motif results in internalization and delivery of the receptor to the lysosome for degradation. (Dietrich, J. et al. (1994) EMBO J. 13:2156-2166.)

The information provided by the amino acid motifs is used by the trafficking machinery
 15 to sequester and package the protein into vesicles, and then deliver it to the appropriate location. Sorting nexin-1 (SNX1) is an example of a protein involved in the recognition of motifs involved in lysosomal targeting. Molecules targeted for the lysosome that require SNX1 include the carboxypeptidase Y sorting receptor and the EGF receptor. In the absence of SNX1, these molecules become mislocalized. (Kurten, R.C., Cadena, D.L., and Gill, G.N. (1996) Science
 20 272:1008-1010; and Horazdovsky, B.F. et al. (1997) Mol. Biol. Cell 8:1529-1541.) The adaptor protein (AP) complex, which triggers assembly of clathrin on membranes to form vesicles, is also involved in sequestration of proteins for delivery to subcellular locations. AP-1 vesicles, which form at the Golgi, include cation-independent and cation-dependent mannose-6-phosphate
 25 plasma membrane, include TGN38 (Stephens, supra) and ligand-bound TCR (Dietrich, supra.) TGN38-containing vesicles are delivered to the TGN and TCR-containing vesicles are delivered to the lysosome.

Once molecules containing targeting motifs have been sequestered and packaged into vesicles, the vesicles need to be delivered to the appropriate location. This delivery process
 30 involves another set of proteins. The Rab family of GTPases are involved in this process via a mechanism not clearly understood. Several Rab proteins have been described, each associated with a particular organelle. For example, Rab3 is associated with the plasma membrane, Rab4 with the sorting endosome, and Rab11 with the recycling endosome. There are also Rabs specific to cell types and functions. For example, Rab3A is specifically involved in synaptic vesicle

WO 00/12703

PCT/US99/19616

exocytosis in stimulated nerve cells, and Rab4b is involved in glucose transporter-4 (GluT4) translocation in insulin-stimulated adipocytes. (James and Piper, supra.)

The discovery of new protein transport-associated molecules and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the
5 diagnosis, prevention, and treatment of cell proliferative and secretory disorders.

SUMMARY OF THE INVENTION

The invention features substantially purified polypeptides, protein transport-associated
10 molecules, referred to collectively as "PTAM". In one aspect, the invention provides a substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 (SEQ ID NO:1-8), and fragments thereof.

The invention further provides a substantially purified variant having at least 90% amino
15 acid identity to at least one of the amino acid sequences selected from the group consisting of SEQ ID NO:1-8, and fragments thereof. The invention also provides an isolated and purified polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof. The invention also includes an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity
20 to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof.

Additionally, the invention provides an isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments
25 thereof. The invention also provides an isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide encoding the polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof.

The invention also provides an isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16
30 (SEQ ID NO:9-16), and fragments thereof. The invention further provides an isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, and fragments thereof. The invention also provides an isolated and purified polynucleotide having a sequence

which is complementary to the polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, and fragments thereof.

The invention also provides a method for detecting a polynucleotide in a sample containing nucleic acids, the method comprising the steps of (a) hybridizing the complement of the polynucleotide sequence to at least one of the polynucleotides of the sample, thereby forming a hybridization complex; and (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of a polynucleotide in the sample. In one aspect, the method further comprises amplifying the polynucleotide prior to hybridization.

The invention further provides an expression vector containing at least a fragment of the polynucleotide encoding the polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof. In another aspect, the expression vector is contained within a host cell.

The invention also provides a method for producing a polypeptide, the method comprising the steps of: (a) culturing the host cell containing an expression vector containing at least a fragment of a polynucleotide under conditions suitable for the expression of the polypeptide; and (b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention further includes a purified antibody which binds to a polypeptide selected from the group consisting of SEQ ID NO:1-8, and fragments thereof. The invention also provides a purified agonist and a purified antagonist to the polypeptide.

The invention also provides a method for treating or preventing a disorder associated with decreased expression or activity of PTAM, the method comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition comprising a substantially purified polypeptide having the amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof, in conjunction with a suitable pharmaceutical carrier.

The invention also provides a method for treating or preventing a disorder associated with increased expression or activity of PTAM, the method comprising administering to a subject in need of such treatment an effective amount of an antagonist of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1-8, and fragments thereof.

BRIEF DESCRIPTION OF THE TABLES

Table 1 shows nucleotide and polypeptide sequence identification numbers (SEQ ID NO), clone identification numbers (clone ID), cDNA libraries, and cDNA fragments used to assemble full-length sequences encoding PTAM.

5 Table 2 shows features of each polypeptide sequence including potential motifs, homologous sequences, and methods and algorithms used for identification of PTAM.

Table 3 shows the tissue-specific expression patterns of each nucleic acid sequence as determined by northern analysis, diseases or disorders associated with these tissues, and the vector into which each cDNA was cloned.

10 Table 4 describes the tissues used to construct the cDNA libraries from which Incyte cDNA clones encoding PTAM were isolated.

Table 5 shows the programs, their descriptions, references, and threshold parameters used to analyze PTAM.

15 DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the
20 present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled
25 in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and
30 methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

WO 00/12703

PCT/US99/19616

DEFINITIONS

“PTAM” refers to the amino acid sequences of substantially purified PTAM obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and preferably the human species, from any source, whether natural, synthetic,
5 semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which, when bound to PTAM, increases or prolongs the duration of the effect of PTAM. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of PTAM.

An “allelic variant” is an alternative form of the gene encoding PTAM. Allelic variants
10 may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination
15 with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding PTAM include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polynucleotide the same as PTAM or a polypeptide with at least one functional characteristic of PTAM. Included within this definition are polymorphisms which may or may not be readily detectable using a particular
20 oligonucleotide probe of the polynucleotide encoding PTAM, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding PTAM. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent PTAM. Deliberate amino acid substitutions may be made
25 on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of PTAM is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, positively charged amino acids may include lysine and arginine, and amino acids with uncharged polar head groups having similar hydrophilicity values may include leucine, isoleucine,
30 and valine; glycine and alanine; asparagine and glutamine; serine and threonine; and phenylalanine and tyrosine.

The terms “amino acid” or “amino acid sequence” refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic molecules. In this context, “fragments,” “immunogenic fragments,” or “antigenic

WO 00/12703

PCT/US99/19616

fragments" refer to fragments of PTAM which are preferably at least 5 to about 15 amino acids in length, most preferably at least 14 amino acids, and which retain some biological activity or immunological activity of PTAM. Where "amino acid sequence" is recited to refer to an amino acid sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known in the art.

10 The term "antagonist" refers to a molecule which, when bound to PTAM, decreases the amount or the duration of the effect of the biological or immunological activity of PTAM. Antagonists may include proteins, nucleic acids, carbohydrates, antibodies, or any other molecules which decrease the effect of PTAM.

The term "antibody" refers to intact molecules as well as to fragments thereof, such as Fab, F(ab')₂, and Fv fragments, which are capable of binding the epitopic determinant. Antibodies that bind PTAM polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

The term "antigenic determinant" refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (given regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition containing a nucleic acid sequence which is complementary to the "sense" strand of a specific nucleic acid sequence. Antisense molecules may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and to block either transcription or translation. The designation "negative" can refer to the antisense strand, and the designation "positive" can refer to the sense strand.

The term "biologically active," refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic PTAM, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with
5 specific antibodies.

The terms "complementary" or "complementarity" refer to the natural binding of polynucleotides by base pairing. For example, the sequence "5' A-G-T 3'" bonds to the complementary sequence "3' T-C-A 5'." Complementarity between two single-stranded molecules may be "partial," such that only some of the nucleic acids bind, or it may be "complete," such that
10 total complementarity exists between the single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of the hybridization between the nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands, and in the design and use of peptide nucleic acid (PNA) molecules.

15 A "composition comprising a given polynucleotide sequence" or a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding PTAM or fragments of PTAM may be employed as hybridization probes. The probes may be stored in
20 freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been resequenced to
25 resolve uncalled bases, extended using XL-PCR kit (Perkin-Elmer, Norwalk CT) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly, such as the GELVIEW Fragment Assembly system (GCG, Madison WI). Some sequences have been both extended and assembled to produce the consensus sequence.

30 The term "correlates with expression of a polynucleotide" indicates that the detection of the presence of nucleic acids, the same or related to a nucleic acid sequence encoding PTAM, by northern analysis is indicative of the presence of nucleic acids encoding PTAM in a sample, and thereby correlates with expression of the transcript from the polynucleotide encoding PTAM.

WO 00/12703

PCT/US99/19616

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to the chemical modification of a polypeptide sequence, or a polynucleotide sequence. Chemical modifications of a polynucleotide sequence can include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

The term "similarity" refers to a degree of complementarity. There may be partial similarity or complete similarity. The word "identity" may substitute for the word "similarity." A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to as "substantially similar." The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization, and the like) under conditions of reduced stringency. A substantially similar sequence or hybridization probe will compete for and inhibit the binding of a completely similar (identical) sequence to the target sequence under conditions of reduced stringency. This is not to say that conditions of reduced stringency are such that non-specific binding is permitted, as reduced stringency conditions require that the binding of two sequences to one another be a specific (i.e., a selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% similarity or identity). In the absence of non-specific binding, the substantially similar sequence or probe will not hybridize to the second non-complementary target sequence.

The phrases "percent identity" or "% identity" refer to the percentage of sequence similarity found in a comparison of two or more amino acid or nucleic acid sequences. Percent identity can be determined electronically, e.g., by using the MEGALIGN program (DNASTAR, Madison WI). The MEGALIGN program can create alignments between two or more sequences according to different methods, e.g., the clustal method. (See, e.g., Higgins, D.G. and P.M. Sharp (1988) Gene 73:237-244.) The clustal algorithm groups sequences into clusters by examining the distances between all pairs. The clusters are aligned pairwise and then in groups. The percentage similarity between two amino acid sequences, e.g., sequence A and sequence B, is calculated by dividing the length of sequence A, minus the number of gap residues in sequence A, minus the number of gap residues in sequence B, into the sum of the residue matches between sequence A

WO 00/12703

PCT/US99/19616

and sequence B, times one hundred. Gaps of low or of no similarity between the two amino acid sequences are not included in determining percentage similarity. Percent identity between nucleic acid sequences can also be counted or calculated by other methods known in the art, e.g., the Jotun Hein method. (See, e.g., Hein, J. (1990) Methods Enzymol. 183:626-645.) Identity between
5 sequences can also be determined by other methods known in the art, e.g., by varying hybridization conditions.

"Human artificial chromosomes" (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size, and which contain all of the elements required for stable mitotic chromosome segregation and maintenance.

10 The term "humanized antibody" refers to antibody molecules in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

"Hybridization" refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

15 The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C_0t or R_0t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate
20 substrate to which cells or their nucleic acids have been fixed).

The words "insertion" or "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, to the sequence found in the naturally occurring molecule.

"Immune response" can refer to conditions associated with inflammation, trauma, immune
25 disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

The term "microarray" refers to an arrangement of distinct polynucleotides on a substrate.

The terms "element" or "array element" in a microarray context, refer to hybridizable
30 polynucleotides arranged on the surface of a substrate.

The term "modulate" refers to a change in the activity of PTAM. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of PTAM.

The phrases "nucleic acid" or "nucleic acid sequence," as used herein, refer to a nucleotide, oligonucleotide, polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any

5 DNA-like or RNA-like material. In this context, "fragments" refers to those nucleic acid sequences which comprise a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:9-16, for example, as distinct from any other sequence in the same genome. For example, a fragment of SEQ ID NO:9-16 is useful in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:9-16 from related polynucleotide

10 sequences. A fragment of SEQ ID NO:9-16 is at least about 15-20 nucleotides in length. The precise length of the fragment of SEQ ID NO:9-16 and the region of SEQ ID NO:9-16 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment. In some cases, a fragment, when translated, would produce polypeptides retaining some functional characteristic, e.g., antigenicity, or structural domain

15 characteristic, e.g., ATP-binding site, of the full-length polypeptide.

The terms "operably associated" or "operably linked" refer to functionally related nucleic acid sequences. A promoter is operably associated or operably linked with a coding sequence if the promoter controls the translation of the encoded polypeptide. While operably associated or operably linked nucleic acid sequences can be contiguous and in the same reading frame, certain

20 genetic elements, e.g., repressor genes, are not contiguously linked to the sequence encoding the polypeptide but still bind to operator sequences that control expression of the polypeptide.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to 60 nucleotides, preferably about 15 to 30 nucleotides, and most preferably about 20 to 25 nucleotides, which can be used in PCR amplification or in a hybridization assay or

25 microarray. "Oligonucleotide" is substantially equivalent to the terms "amplimer," "primer," "oligomer," and "probe," as these terms are commonly defined in the art.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition.

30 PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

The term "sample" is used in its broadest sense. A sample suspected of containing nucleic acids encoding PTAM, or fragments thereof, or PTAM itself, may comprise a bodily fluid; an

WO 00/12703

PCT/US99/19616

extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

The terms "specific binding" or "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, or an antagonist. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide containing the epitope A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "stringent conditions" refers to conditions which permit hybridization between polynucleotides and the claimed polynucleotides. Stringent conditions can be defined by salt concentration, the concentration of organic solvent, e.g., formamide, temperature, and other conditions well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least about 60% free, preferably about 75% free, and most preferably about 90% free from other components with which they are naturally associated.

A "substitution" refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers, microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

"Transformation" describes a process by which exogenous DNA enters and changes a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, viral infection, electroporation, heat shock, lipofection, and particle bombardment. The term "transformed" cells includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host

WO 00/12703

PCT/US99/19616

chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "variant" of PTAM polypeptides refers to an amino acid sequence that is altered by one or more amino acid residues. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties (e.g., replacement of leucine with isoleucine). More rarely, a variant may have "nonconservative" changes (e.g., replacement of glycine with tryptophan). Analogous minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, LASERGENE software (DNASTAR).

The term "variant," when used in the context of a polynucleotide sequence, may encompass a polynucleotide sequence related to PTAM. This definition may also include, for example, "allelic" (as defined above), "splice," "species," or "polymorphic" variants. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides due to alternate splicing of exons during mRNA processing. The corresponding polypeptide may possess additional functional domains or an absence of domains. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides generally will have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

25 THE INVENTION

The invention is based on the discovery of new human protein transport-associated molecules (PTAM), the polynucleotides encoding PTAM, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative and secretory disorders.

Table 1 lists the Incyte Clones used to derive full length nucleotide sequences encoding PTAM. Columns 1 and 2 show the sequence identification numbers (SEQ ID NO) of the amino acid and nucleic acid sequences, respectively. Column 3 shows the Clone ID of the Incyte Clone in which nucleic acids encoding each PTAM were first identified, and column 4, the cDNA libraries from which these clones were isolated. Column 5 shows Incyte clones, their

corresponding cDNA libraries, and shotgun sequences useful as fragments in hybridization technologies, and which are part of the consensus nucleotide sequence of each PTAM.

The columns of Table 2 show various properties of the polypeptides of the invention: column 1 references the SEQ ID NO; column 2 shows the number of amino acid residues in each polypeptide; column 3, potential phosphorylation sites; column 4, potential glycosylation sites; column 5, the amino acid residues comprising signature sequences and motifs; column 6, the identity of each protein; and column 7, analytical methods used to identify each protein through sequence homology and protein motifs.

The columns of Table 3 show the tissue-specificity and disease-association of nucleotide sequences encoding PTAM. The first column of Table 3 lists the polynucleotide sequence identifiers. The second column lists tissue categories which express PTAM as a fraction of total tissue categories expressing PTAM. The third column lists the disease classes associated with those tissues expressing PTAM. The fourth column lists the vectors used to subclone the cDNA library.

The following represent unique fragments of the nucleotide sequences encoding PTAM: the fragment of SEQ ID NO:9 from about nucleotide 1324 to about nucleotide 1422; the fragment of SEQ ID NO:10 from about nucleotide 455 to about nucleotide 499; the fragment of SEQ ID NO:11 from about nucleotide 101 to about nucleotide 145; the fragment of SEQ ID NO:12 from about nucleotide 178 to about nucleotide 240; the fragment of SEQ ID NO:13 from about nucleotide 543 to about nucleotide 590; the fragment of SEQ ID NO:14 from about nucleotide 525 to about nucleotide 584; the fragment of SEQ ID NO:15 from about nucleotide 371 to about nucleotide 433; and the fragment of SEQ ID NO:16 from about nucleotide 86 to about nucleotide 145.

The invention also encompasses PTAM variants. A preferred PTAM variant is one which has at least about 80%, more preferably at least about 90%, and most preferably at least about 95% amino acid sequence identity to the PTAM amino acid sequence, and which contains at least one functional or structural characteristic of PTAM.

The invention also encompasses polynucleotides which encode PTAM. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:9-16, which encodes PTAM.

The invention also encompasses a variant of a polynucleotide sequence encoding PTAM. In particular, such a variant polynucleotide sequence will have at least about 70%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding PTAM. A particular aspect of the invention encompasses a

WO 00/12703

PCT/US99/19616

variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:9-16 which has at least about 70%, more preferably at least about 85%, and most preferably at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:9-16. Any one of the polynucleotide variants described
5 above can encode an amino acid sequence which contains at least one functional or structural characteristic of PTAM.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding PTAM, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be
10 produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally occurring PTAM, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode PTAM and its variants are preferably
15 capable of hybridizing to the nucleotide sequence of the naturally occurring PTAM under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PTAM or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which
20 expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PTAM and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally
25 occurring sequence.

The invention also encompasses production of DNA sequences which encode PTAM and PTAM derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to
30 introduce mutations into a sequence encoding PTAM or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:9-16 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.*

WO 00/12703

PCT/US99/19616

152:507-511.) For example, stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and most preferably less than about 250 mM NaCl and 25 mM trisodium citrate. Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while
5 high stringency hybridization can be obtained in the presence of at least about 35% formamide, and most preferably at least about 50% formamide. Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42°C. Varying additional parameters, such as hybridization time, the concentration of detergent, e.g., sodium dodecyl sulfate (SDS), and the inclusion or exclusion
10 of carrier DNA, are well known to those skilled in the art. Various levels of stringency are accomplished by combining these various conditions as needed. In a preferred embodiment, hybridization will occur at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will occur at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 µg/ml denatured salmon sperm DNA (ssDNA). In a
15 most preferred embodiment, hybridization will occur at 42°C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50 % formamide, and 200 µg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.

The washing steps which follow hybridization can also vary in stringency. Wash stringency conditions can be defined by salt concentration and by temperature. As above, wash
20 stringency can be increased by decreasing salt concentration or by increasing temperature. For example, stringent salt concentration for the wash steps will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash steps will ordinarily include temperature of at least about 25°C, more preferably of at least about 42°C, and most preferably of
25 at least about 68°C. In a preferred embodiment, wash steps will occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps will occur at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a most preferred embodiment, wash steps will occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art.

30 Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Perkin-Elmer), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the

WO 00/12703

PCT/US99/19616

ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the Hamilton MICROLAB 2200 (Hamilton, Reno NV), Peltier Thermal Cycler 200 (PTC200; MJ Research, Watertown MA) and the ABI CATALYST 800 (Perkin-Elmer). Sequencing is then carried out using either ABI 373 or 377

5 DNA Sequencing Systems (Perkin-Elmer) or the MEGABACE capillary electrophoresis system (Molecular Dynamics, Sunnyvale CA). The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

10 The nucleic acid sequences encoding PTAM may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods

15 Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial

20 chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-306.) Additionally, one may use PCR,

25 nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 Primer Analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of

30 about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T)

library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Perkin-Elmer), and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode PTAM may be cloned in recombinant DNA molecules that direct expression of PTAM, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express PTAM.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter PTAM-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

In another embodiment, sequences encoding PTAM may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucl. Acids Res. Symp. Ser. 215-223, and Horn, T. et al. (1980) Nucl. Acids Res. Symp. Ser. 225-232.) Alternatively, PTAM itself or a fragment thereof may be synthesized using chemical methods. For example, peptide synthesis can be performed using various solid-phase techniques. (See, e.g., Roberge, J.Y. et al. (1995) Science 269:202-204.) Automated synthesis may be achieved using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Additionally, the amino acid sequence of PTAM, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

WO 00/12703

PCT/US99/19616

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g, Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.) The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH
5 Freeman, New York NY.)

In order to express a biologically active PTAM, the nucleotide sequences encoding PTAM or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers,
10 constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding PTAM. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding PTAM. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding PTAM and its initiation
15 codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic.
20 The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding PTAM and appropriate transcriptional and
25 translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

30 A variety of expression vector/host systems may be utilized to contain and express sequences encoding PTAM. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus); plant cell systems transformed with viral expression vectors

WO 00/12703

PCT/US99/19616

(e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected
5 depending upon the use intended for polynucleotide sequences encoding PTAM. For example, routine cloning, subcloning, and propagation of polynucleotide sequences encoding PTAM can be achieved using a multifunctional E. coli vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSPORT1 plasmid (Life Technologies). Ligation of sequences encoding PTAM into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure
10 for identification of transformed bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of PTAM are needed, e.g. for the production of antibodies, vectors which direct high level expression of PTAM
15 may be used. For example, vectors containing the strong, inducible T5 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of PTAM. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH, may be used in the yeast Saccharomyces cerevisiae or Pichia pastoris. In addition, such vectors
20 direct either the secretion or intracellular retention of expressed proteins and enable integration of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra; Grant et al. (1987) Methods Enzymol. 153:516-54; and Scorer, C. A. et al. (1994) Bio/Technology 12:181-184.)

Plant systems may also be used for expression of PTAM. Transcription of sequences
25 encoding PTAM may be driven viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV. (Takamatsu, N. (1987) EMBO J. 6:307-311.) Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell
30 Differ. 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding PTAM may be ligated

WO 00/12703

PCT/US99/19616

into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses PTAM in host cells. (See, e.g., Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. 81:3655-3659.) In addition, transcription enhancers, such as the

5 Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino

10 polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of PTAM in cell lines is preferred. For example, sequences encoding PTAM can be transformed into cell lines using expression vectors which may contain viral origins of replication

15 and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed

20 cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase genes, for use in *tk* or *ap^r* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite,

25 antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* or *pat* confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14) Additional selectable genes have been

30 described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech), β glucuronidase and its substrate β -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein

WO 00/12703

PCT/US99/19616

expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) *Methods Mol. Biol.* 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding PTAM is inserted within a marker gene sequence, transformed cells containing sequences encoding PTAM can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding PTAM under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

10 In general, host cells that contain the nucleic acid sequence encoding PTAM and that express PTAM may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or
15 protein sequences.

Immunological methods for detecting and measuring the expression of PTAM using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing
20 monoclonal antibodies reactive to two non-interfering epitopes on PTAM is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St Paul MN, Sect. IV; Coligan, J. E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical
25 Protocols, Humana Press, Totowa NJ).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding PTAM include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled
30 nucleotide. Alternatively, the sequences encoding PTAM, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by

WO 00/12703

PCT/US99/19616

Amersham Pharmacia Biotech, Promega (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

5 Host cells transformed with nucleotide sequences encoding PTAM may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode PTAM may be designed to contain signal
10 sequences which direct secretion of PTAM through a prokaryotic or eukaryotic cell membrane.

 In addition, a host cell strain may be chosen for its ability to modulate expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro"
15 form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC, Bethesda MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

20 In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding PTAM may be ligated to a heterologous sequence resulting in translation of a fusion protein in any of the aforementioned host systems. For example, a chimeric PTAM protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of PTAM activity. Heterologous
25 protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide,
30 calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the PTAM encoding sequence and the heterologous protein sequence, so that PTAM may be cleaved away from the heterologous

WO 00/12703

PCT/US99/19616

moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch 10.) A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled PTAM may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract systems (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, preferably ³⁵S-methionine.

Fragments of PTAM may be produced not only by recombinant production, but also by direct peptide synthesis using solid-phase techniques. (See, e.g., Creighton, supra pp. 55-60.) Protein synthesis may be performed by manual techniques or by automation. Automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin-Elmer). Various fragments of PTAM may be synthesized separately and then combined to produce the full length molecule.

15

THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between PTAM and protein transport-associated molecules. In addition, the expression of PTAM is closely associated with cell proliferation. Therefore, in cell proliferative and secretory disorders where the expression or activity of PTAM is low, it is desirable to increase the expression or activity of PTAM. In cell proliferative and secretory disorders where the expression or activity of PTAM is high, it is desirable to decrease the expression or activity of PTAM.

Therefore, in one embodiment, PTAM or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with cell proliferation or secretion in which the expression or activity of PTAM is decreased. Examples of such disorders include, but are not limited to, cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; immune disorders such as actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis,

30

WO 00/12703

PCT/US99/19616

diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and secretory disorders such as cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, diabetes insipidus, hyper- and hypoglycemia, goiter, Cushing's disease, and other conditions associated with abnormal vesicle trafficking, such as allergies, including hay fever, asthma, and urticaria (hives), autoimmune hemolytic anemia, Chediak-Higashi syndrome, and toxic shock syndrome.

In another embodiment, a vector capable of expressing PTAM or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder including, but not limited to, those described above.

In a further embodiment, a pharmaceutical composition comprising a substantially purified PTAM in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of PTAM may be administered to a subject to treat or prevent a disorder including, but not limited to, those listed above.

In a further embodiment, an antagonist of PTAM may be administered to a subject to treat or prevent a disorder in which the expression or activity of PTAM is increased. Examples of such disorders include, but are not limited to, those described above. In one aspect, an antibody which specifically binds PTAM may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express PTAM.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding PTAM may be administered to a subject to treat or prevent a disorder including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences, or vectors of the invention may be administered in combination with

WO 00/12703

PCT/US99/19616

other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to
5 achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of PTAM may be produced using methods which are generally known in the art. In particular, purified PTAM may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind PTAM. Antibodies to PTAM may
10 also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice,
15 humans, and others may be immunized by injection with PTAM or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol.
20 Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PTAM have an amino acid sequence consisting of at least about 5 amino acids, and, more preferably, of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides,
25 or fragments are identical to a portion of the amino acid sequence of the natural protein and contain the entire amino acid sequence of a small, naturally occurring molecule. Short stretches of PTAM amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to PTAM may be prepared using any technique which provides for
30 the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and
5 Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce PTAM-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton D.R. (1991) Proc. Natl. Acad. Sci. 88:10134-10137.)

10 Antibodies may also be produced by inducing in vivo production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for PTAM may also be
15 generated. For example, such fragments include, but are not limited to, F(ab')₂ fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

20 Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between PTAM and its specific antibody. A two-site, monoclonal-based immunoassay utilizing
25 monoclonal antibodies reactive to two non-interfering PTAM epitopes is preferred, but a competitive binding assay may also be employed (Pound, supra.)

In another embodiment of the invention, the polynucleotides encoding PTAM, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the complement of the polynucleotide encoding PTAM may be used in situations in which it would be
30 desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding PTAM. Thus, complementary molecules or fragments may be used to modulate PTAM activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger

WO 00/12703

PCT/US99/19616

fragments can be designed from various locations along the coding or control regions of sequences encoding PTAM.

Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. Methods which are well known to those skilled in the art can be used to construct vectors to express nucleic acid sequences complementary to the polynucleotides encoding PTAM. (See, e.g., Sambrook, *supra*; Ausubel, 1995, *supra*.)

Genes encoding PTAM can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide, or fragment thereof, encoding PTAM. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector, and may last even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5', or regulatory regions of the gene encoding PTAM. Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, *Molecular and Immunologic Approaches*, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding PTAM.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may

WO 00/12703

PCT/US99/19616

be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding PTAM. Such DNA sequences may be incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

An additional embodiment of the invention relates to the administration of a pharmaceutical or sterile composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of PTAM, antibodies to PTAM, and mimetics, agonists, antagonists, or inhibitors of PTAM. The compositions may be administered alone or in combination with at least one other agent, such as a stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical

WO 00/12703

PCT/US99/19616

carrier including, but not limited to, saline, buffered saline, dextrose, and water. The compositions may be administered to a patient alone, or in combination with other agents, drugs, or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combining active compounds with solid excipient and processing the resultant mixture of granules (optionally, after grinding) to obtain tablets or dragee cores. Suitable auxiliaries can be added, if desired. Suitable excipients include carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, and sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums, including arabic and tragacanth; and proteins, such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, and alginic acid or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with fillers or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft

WO 00/12703

PCT/US99/19616

capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate, triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents to increase the solubility of the compounds and allow for the preparation of highly concentrated solutions.

For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1 mM to 50 mM histidine, 0.1% to 2% sucrose, and 2% to 7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of PTAM, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells or in animal models such as mice, rats, rabbits, dogs, or pigs. An animal model may also be used to determine the appropriate concentration range and

WO 00/12703

PCT/US99/19616

route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example PTAM or fragments thereof, antibodies of PTAM, and agonists, antagonists or inhibitors of PTAM, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the ED_{50} (the dose therapeutically effective in 50% of the population) or LD_{50} (the dose lethal to 50% of the population) statistics. The dose ratio of therapeutic to toxic effects is the therapeutic index, and it can be expressed as the ED_{50}/LD_{50} ratio. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the ED_{50} with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from about $0.1 \mu\text{g}$ to $100,000 \mu\text{g}$, up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

30 DIAGNOSTICS

In another embodiment, antibodies which specifically bind PTAM may be used for the diagnosis of cell proliferative and secretory disorders characterized by expression of PTAM, or in assays to monitor patients being treated with PTAM or agonists, antagonists, or inhibitors of PTAM. Antibodies useful for diagnostic purposes may be prepared in the same manner as

WO 00/12703

PCT/US99/19616

described above for therapeutics. Diagnostic assays for PTAM include methods which utilize the antibody and a label to detect PTAM in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which
5 are described above, are known in the art and may be used.

A variety of protocols for measuring PTAM, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of PTAM expression. Normal or standard values for PTAM expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to
10 PTAM under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, preferably by photometric means. Quantities of PTAM expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

15 In another embodiment of the invention, the polynucleotides encoding PTAM may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of PTAM may be correlated with disease. The diagnostic assay may be used to determine absence,
20 presence, and excess expression of PTAM, and to monitor regulation of PTAM levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding PTAM or closely related molecules may be used to identify nucleic acid sequences which encode PTAM. The specificity
25 of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification (maximal, high, intermediate, or low), will determine whether the probe identifies only naturally occurring sequences encoding PTAM, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably
30 have at least 50% sequence identity to any of the PTAM encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:9-16 or from genomic sequences including promoters, enhancers, and introns of the PTAM gene.

WO 00/12703

PCT/US99/19616

Means for producing specific hybridization probes for DNAs encoding PTAM include the cloning of polynucleotide sequences encoding PTAM or PTAM derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as ^{32}P or ^{35}S , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding PTAM may be used for the diagnosis of cell proliferative and secretory disorders associated with expression of PTAM. Examples of such disorders include, but are not limited to, cell proliferative disorders such as cancers, including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; immune disorders such as actinic keratosis, acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, arteriosclerosis, asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, bronchitis, bursitis, cholecystitis, cirrhosis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, paroxysmal nocturnal hemoglobinuria, hepatitis, hypereosinophilia, irritable bowel syndrome, episodic lymphopenia with lymphocytotoxins, mixed connective tissue disease (MCTD), multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, myelofibrosis, osteoarthritis, osteoporosis, pancreatitis, polycythemia vera, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, primary thrombocythemia, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; and secretory disorders such as cystic fibrosis, glucose-galactose malabsorption syndrome, hypercholesterolemia, diabetes insipidus, hyper- and hypoglycemia, goiter, Cushing's disease, and other conditions associated with abnormal vesicle trafficking, such as allergies, including hay fever, asthma, and urticaria (hives), autoimmune hemolytic anemia, Chediak-Higashi syndrome, and toxic shock syndrome. The polynucleotide sequences encoding PTAM may be used in Southern or northern analysis, dot blot,

WO 00/12703

PCT/US99/19616

or other membrane-based technologies; in PCR technologies; in dipstick, pin, and ELISA assays; and in microarrays utilizing fluids or tissues from patients to detect altered PTAM expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding PTAM may be useful in assays
5 that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding PTAM may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the patient sample is significantly
10 altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding PTAM in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of
15 PTAM, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding PTAM, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially
20 purified polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to determine if the level of expression in
25 the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or over-expressed) in biopsied tissue from an individual may indicate a predisposition for the
30 development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding PTAM may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced in vitro. Oligomers will preferably contain a fragment of a polynucleotide encoding PTAM, or a fragment of a polynucleotide complementary to the polynucleotide encoding PTAM, and will be employed under optimized conditions for identification of a specific gene or condition. Oligomers may also be employed under less stringent conditions for detection or quantitation of closely related DNA or RNA sequences.

Methods which may also be used to quantitate the expression of PTAM include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as targets in a microarray. The microarray can be used to monitor the expression level of large numbers of genes simultaneously and to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, and to develop and monitor the activities of therapeutic agents.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.)

In another embodiment of the invention, nucleic acid sequences encoding PTAM may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical chromosome mapping techniques and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, supra, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM) site. Correlation between the
5 location of the gene encoding PTAM on a physical chromosomal map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder. The nucleotide sequences of the invention may be used to detect differences in gene sequences among normal, carrier, and affected individuals.

In situ hybridization of chromosomal preparations and physical mapping techniques, such
10 as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms by physical mapping. This provides valuable information to investigators searching for disease genes using
15 positional cloning or other gene discovery techniques. Once the disease or syndrome has been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) Nature 336:577-580.) The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal
20 location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, PTAM, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of
25 binding complexes between PTAM and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with PTAM, or
30 fragments thereof, and washed. Bound PTAM is then detected by methods well known in the art. Purified PTAM can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

WO 00/12703

PCT/US99/19616

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding PTAM specifically compete with a test compound for binding PTAM. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with PTAM.

5 In additional embodiments, the nucleotide sequences which encode PTAM may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the
10 preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications, and publications mentioned above and below, in particular U.S. Ser. No. 60/098,206, are hereby expressly incorporated by reference.

15

EXAMPLES

I. Construction of cDNA Libraries

RNA was purchased from Clontech or isolated from tissues described in Table 4. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were
20 homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

25 Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA purity. In some cases, RNA was treated with DNase. For most libraries, poly(A⁺) RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Valencia CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the
30 POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel,

WO 00/12703

PCT/US99/19616

1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or
5 SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), or pINCY (Incyte Pharmaceuticals, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from
10 Stratagene or DH5 α , DH10B, or ElectroMAX DH10B from Life Technologies. **II.**

Isolation of cDNA Clones

Plasmids were recovered from host cells by in vivo excision, using the UNIZAP vector system (Stratagene) or cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep
15 purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the REAL Prep 96 plasmid kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in
20 a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14.) Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a Fluoroskan II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

25 **III. Sequencing and Analysis**

The cDNAs were prepared for sequencing using the ABI CATALYST 800 (Perkin-Elmer) or the HYDRA microdispenser (Robbins Scientific, Sunnyvale CA) or MICROLAB 2200 (Hamilton, Reno NV) systems in combination with the PTC-200 thermal cyclers (MJ Research, Watertown MA). The cDNAs were sequenced using the ABI PRISM 373 or 377 sequencing
30 systems (Perkin-Elmer) and standard ABI protocols, base calling software, and kits. In one alternative, cDNAs were sequenced using the MEGABACE 1000 capillary electrophoresis sequencing system (Molecular Dynamics, Sunnyvale CA). In another alternative, the cDNAs were amplified and sequenced using the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Perkin-Elmer). In yet another alternative, cDNAs were sequenced using solutions

WO 00/12703

PCT/US99/19616

and dyes from Amersham Pharmacia Biotech. Reading frames for the ESTs were determined using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7.) Some of the cDNA sequences were selected for extension using the techniques disclosed in Example V.

The polynucleotide sequences derived from cDNA, extension, and shotgun sequencing
 5 were assembled and analyzed using a combination of software programs which utilize algorithms well known to those skilled in the art. Table 5 summarizes the software programs, descriptions, references, and threshold parameters used. The first column of Table 5 shows the tools, programs, and algorithms used, the second column provides a brief description thereof, the third column presents the references which are incorporated by reference herein, and the fourth column
 10 presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the probability the greater the homology). Sequences were analyzed using MACDNASIS PRO software (Hitachi Software Engineering, S. San Francisco CA) and LASERGENE software (DNASTAR).

The polynucleotide sequences were validated by removing vector, linker, and polyA
 15 sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The sequences were then queried against a selection of public databases such as GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS to acquire annotation, using programs based on BLAST, FASTA, and BLIMPS. The sequences were assembled into full length polynucleotide
 20 sequences using programs based on Phred, Phrap, and Consed, and were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The full length polynucleotide sequences were translated to derive the corresponding full length amino acid sequences, and these full length sequences were subsequently analyzed by querying against databases such as the GenBank databases (described above), SwissProt, BLOCKS, PRINTS,
 25 PFAM, and Prosite.

The programs described above for the assembly and analysis of full length polynucleotide and amino acid sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:8-14. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies were described in The Invention section above.

30 IV. Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, supra, ch. 7; Ausubel, 1995, supra, ch. 4 and 16.)

WO 00/12703

PCT/US99/19616

Analogous computer techniques applying BLAST were used to search for identical or related molecules in nucleotide databases such as GenBank or LIFESEQ database (Incyte Pharmaceuticals). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar. The basis of the search is the product score, which is defined as:

$$\frac{\% \text{ sequence identity} \times \% \text{ maximum BLAST score}}{100}$$

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1% to 2% error, and, with a product score of 70, the match will be exact. Similar molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analyses are reported as a list of libraries in which the transcript encoding PTAM occurred. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library. Further analyses produced the percentage values of tissue-specific and disease expression which are reported in Table 3.

20 V. Extension of PTAM Encoding Polynucleotides

The nucleic acid sequences of Incyte ESTs 12033, 1209687, 1717058, 1749964, 1856357, 1871275, 2645806, and 3437773 were used to design oligonucleotide primers for extending partial nucleotide sequence to full length. For each nucleic acid sequence, one primer was synthesized to initiate extension of an antisense polynucleotide, and the other was synthesized to initiate extension of a sense polynucleotide. Primers were used to facilitate the extension of the known sequence "outward" which generates amplicons containing new unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (Life Technologies) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

WO 00/12703

PCT/US99/19616

High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin-Elmer) and thoroughly mixing the enzyme and reaction mix. PCR was performed using the PTC200 thermal cycler (M.J. Research) beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, with the following parameters:

5	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
10	Step 6	68° C for 7 min
	Step 7	Repeat steps 4-6 for an additional 15 cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
15	Step 11	Repeat steps 8-10 for an additional 12 cycles
	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

A 5 μ l to 10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6% to 0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using the QIAQUICK kit (QIAGEN), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2 to 3 hours, or overnight at 16° C. Competent *E. coli* cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l of SOC medium. (See, e.g., Sambrook, *supra*, Appendix A, p. 2.) After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB) agar (See, e.g., Sambrook, *supra*, Appendix A, p. 1) containing carbenicillin (2x carb). The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x carb medium placed in an individual well of an appropriate commercially-available sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and, after dilution 1:10 with water, 5 μ l from each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

WO 00/12703

PCT/US99/19616

- | | | |
|---|--------|--|
| | Step 1 | 94° C for 60 sec |
| | Step 2 | 94° C for 20 sec |
| | Step 3 | 55° C for 30 sec |
| | Step 4 | 72° C for 90 sec |
| 5 | Step 5 | Repeat steps 2-4 for an additional 29 cycles |
| | Step 6 | 72° C for 180 sec |
| | Step 7 | 4° C (and holding) |

Aliquots of the PCR reactions were run on agarose gels together with molecular weight
 10 markers. The sizes of the PCR products were compared to the original partial cDNAs, and
 appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequences of SEQ ID NO:9-16 are used to obtain 5'
 regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and
 an appropriate genomic library.

15 VI. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:9-16 are employed to screen cDNAs,
 genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20
 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide
 fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06
 20 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250 μ Ci of
 [γ -³²P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase
 (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a
 SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech).
 An aliquot containing 10⁷ counts per minute of the labeled probe is used in a typical membrane-
 25 based hybridization analysis of human genomic DNA digested with one of the following
 endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon
 membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16
 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature
 30 under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl
 sulfate. After XOMAT-AR film (Eastman Kodak, Rochester NY) is exposed to the blots to film
 for several hours, hybridization patterns are compared visually.

VII. Microarrays

A chemical coupling procedure and an ink jet device can be used to synthesize array
 35 elements on the surface of a substrate. (See, e.g., Baldeschweiler, supra.) An array analogous to a
 dot or slot blot may also be used to arrange and link elements to the surface of a substrate using
 thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced by

WO 00/12703

PCT/US99/19616

hand or using available methods and machines and contain any appropriate number of elements. After hybridization, nonhybridized probes are removed and a scanner used to determine the levels and patterns of fluorescence. The degree of complementarity and the relative abundance of each probe which hybridizes to an element on the microarray may be assessed through analysis of the
5 scanned images.

Full-length cDNAs, Expressed Sequence Tags (ESTs), or fragments thereof may comprise the elements of the microarray. Fragments suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). Full-length cDNAs, ESTs, or fragments thereof corresponding to one of the nucleotide sequences of the
10 present invention, or selected at random from a cDNA library relevant to the present invention, are arranged on an appropriate substrate, e.g., a glass slide. The cDNA is fixed to the slide using, e.g., UV cross-linking followed by thermal and chemical treatments and subsequent drying. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645.) Fluorescent probes are prepared and used for hybridization to the elements on the substrate. The
15 substrate is analyzed by procedures described above.

VIII. Complementary Polynucleotides

Sequences complementary to the PTAM-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring PTAM. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same
20 procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of PTAM. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the
25 PTAM-encoding transcript.

IX. Expression of PTAM

Expression and purification of PTAM is achieved using bacterial or virus-based expression systems. For expression of PTAM in bacteria, cDNA is subcloned into an appropriate
30 vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express PTAM upon induction with isopropyl beta-

WO 00/12703

PCT/US99/19616

D-thiogalactopyranoside (IPTG). Expression of PTAM in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding PTAM by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E. K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, PTAM is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from PTAM at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, supra, ch 10 and 16.) Purified PTAM obtained by these methods can be used directly in the following activity assay.

X. Functional Assays

PTAM function is assessed by expressing the sequences encoding PTAM at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include pCMV SPORT (Life Technologies) and pCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10 μ g of recombinant vector are transiently transfected into a human cell line, preferably of endothelial or hematopoietic origin, using either liposome formulations or electroporation. 1-2 μ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion

protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP, and to evaluate properties, for example, their apoptotic state. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA
 5 content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of
 10 fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M. G. (1994) Flow Cytometry, Oxford, New York NY.

The influence of PTAM on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding PTAM and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved
 15 regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding PTAM and other genes of interest can be analyzed by northern analysis or microarray techniques.

20 **XI. Production of PTAM Specific Antibodies**

PTAM substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the PTAM amino acid sequence is analyzed using LASERGENE software
 25 (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, supra, ch. 11.)

Typically, oligopeptides 15 residues in length are synthesized using an ABI 431A
 30 Peptide Synthesizer (Perkin-Elmer) using fmoc-chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, supra.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for

WO 00/12703

PCT/US99/19616

antipeptide activity by, for example, binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

XII. Purification of Naturally Occurring PTAM Using Specific Antibodies

Naturally occurring or recombinant PTAM is substantially purified by immunoaffinity
5 chromatography using antibodies specific for PTAM. An immunoaffinity column is constructed by covalently coupling anti-PTAM antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing PTAM are passed over the immunoaffinity column, and the column is
10 washed under conditions that allow the preferential absorbance of PTAM (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/PTAM binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and PTAM is collected.

XIII. Identification of Molecules Which Interact with PTAM

PTAM, or biologically active fragments thereof, are labeled with ¹²⁵I Bolton-Hunter
15 reagent. (See, e.g., Bolton et al. (1973) Biochem. J. 133:529.) Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled PTAM, washed, and any wells with labeled PTAM complex are assayed. Data obtained using different concentrations of PTAM are used to calculate values for the number, affinity, and association of PTAM with the
20 candidate molecules.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred
25 embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

WO 00/12703

PCT/US99/19616

TABLE 1

Protein SEQ ID NO:	Nucleotide SEQ ID NO:	Clone ID	Library	Fragments
1	9	012033	THP1PLB01	012033H1 (THP1PLB01), 371440H1 (LUNGNOT02), 1835003T6 (BRAINON01), 2184660T6 (SININOT01), 2355213F6 and 2355213T6 (LUNGNOT20), 3564476H1 (SKINNOT05)
2	10	1209687	BRSTNOT02	1209687H1 (BRSTNOT02), 1212604T6 (BRSTTUT01), 2702873H1 (OVRTUT10)
3	11	1717058	UCMCNOT02	015033F1 and 015033R1 (HUVELPB01), 041851R1 (TBLYNOT01), 625952H1 (PGANNOT01), 1580781H1 (DUODNOT01), 1717058F6 and 1717058H1 (UCMCNOT02)
4	12	1749964	STOMTUT02	455769F1 and 455769R1 (KERANOT01), 734407R1 (TONSNOT01), 1688918F6 (PROSTUT10), 1749964H1 (STOMTUT02), 1867108F6 (SKINBIT01), 1917583H1 (PROSNOT06), 1920136R6 (BRSTTUT01), 2683294F6 (SINIUCT01)
5	13	1856357	PROSNOT18	1610265F6 (COLNTUT06), 618761H1 (PGANNOT01), 732969R1 (LUNGNOT03), 874322H1 (LUNGAST01), 968936H1 (BRSTNOT05), 1394835F6 (THYRNOT03), 1856357F6 and 1856357H1 (PROSNOT18), 2788175H1 (BRSTNOT16), 2870537H1 (THYRNOT10), 3359258H1 (PROSTUT16), 3931139H1 (PROSTUT09)
6	14	1871275	SKINBIT01	081150F1 (SYNORAB01), 1509160F1 (LUNGNOT14), 1553311F1 (BLADTUT04), 1871275H1 (SKINBIT01), SBAA02579F1
7	15	2645806	OVRTUT04	2239005F6 (PANCUTUT02), 3598925H1 (DRGTNOT01), 2645806F6 and 2645806H1 (OVRTUT04)
8	16	3437773	PENCNOT05	148721F1 (FIBRNGT01), 1291051F6 (BRAINOT11), 1979290R6 (LUNGNOT03), 2203762F6 (SPLNFET02), 3437773H1 (PENCNOT05)

WO 00/12703

PCT/US99/19616

TABLE 2

Protein Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
1	480	S56 T62 S70 T76 S84 T90 S98 S112 T118 S126 T132 S140 T146 S154 T160 S168 T174 S182 T188 S196 T202 S210 T216 S224 S238 T244 S258 S298 T331 T358 T363 S365 S25 S47 S53 S95 T104 T109 T123 T137 S193 S221 T422	N39 N82 N96 N152 N180 N208 N222 N373 N377	M1-P19 F385-A402	human TGN38 homolog hTGN51	BLAST SPScan HMM
2	140	T8 T26 S53 S57 S73 S98			nuclear transport factor NTF2	BLAST
3	519	S185 T16 S33 S40 S127 S147 S174 S227 T165 S179 T246 T296 T470	N300	K181-Y198	sorting nexin 2	PRINTS BLAST
4	613	S233 S37 S39 S73 T84 S183 T286 T287 S327 S115 T124 S225 S229 S435 S480 S541 S551			novel VHS domain containing protein	BLAST
5	719	S27 S78 T137 S243 S257 S413 T432 T443 S654 S174 T234 S304 S316 S357 T575 S630 S700 T716 Y397 Y600			hook2 protein	BLAST

WO 00/12703

PCT/US99/19616

TABLE 2 cont.

Seq ID NO:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequence	Identification	Analytical Methods
6	175	S72 S101 T145 T171 S89 S139 T162		G2	TCR delta	MOTIFS BLAST
7	142	T3 T9 S54 T99	N123		nuclear transport factor NTF2	BLAST
8	248	T126 T167 T54 T91 S228	N73	G50-S57 K45-C248	Ras family member Rab4b	MOTIFS PFAM BLAST PRINTS

TABLE 3

Polynucleotide Seq ID NO:	Tissue Expression (Fraction of Total)	Disease Class (Fraction of Total)	Vector
9	Hematopoietic/Immune (0.314) Reproductive (0.171) Gastrointestinal (0.143)	Proliferative (0.571) Inflammation (0.485)	PBLUESCRIPT
10	Reproductive (0.500) Cardiovascular (0.143) Hematopoietic/Immune (0.143)	Proliferative (0.643) Inflammation (0.429)	PSPORT1
11	Reproductive (0.256) Hematopoietic/Immune (0.174) Nervous (0.163)	Proliferative (0.651) Inflammation (0.279)	pINCY
12	Reproductive (0.245) Hematopoietic/Immune (0.147) Nervous (0.127)	Proliferative (0.687) Inflammation (0.284)	pINCY
13	Reproductive (0.435) Gastrointestinal (0.130) Nervous (0.101)	Proliferative (0.826) Inflammation (0.217)	pINCY
14	Cardiovascular (0.233) Musculoskeletal (0.233) Gastrointestinal (0.140)	Inflammation (0.535) Cancer (0.395)	pINCY
15	Cardiovascular (0.308) Reproductive (0.231) Nervous (0.154) Gastrointestinal (0.154)	Proliferative (0.846) Inflammation (0.308)	pINCY
16	Nervous (0.245) Hematopoietic/Immune (0.184) Cardiovascular (0.163)	Cancer (0.449) Inflammation (0.367)	pINCY

TABLE 4

Polynucleotide SEQ ID NO:	Clone ID	Library	Library Description
9	012033	THP1PLB01	Library was constructed using RNA isolated from THP-1 cells cultured for 48 hours with 100 ng/ml phorbol ester (PMA), followed by a 4-hour culture in media containing 1 ug/ml LPS. THP-1 (ATCC TIB 202) is a human promonocyte line derived from the peripheral blood of a 1-year-old male with acute monocytic leukemia (ref: Int. J. Cancer (1980) 26:171).
10	1209687	BRSTNOT02	Library was constructed using RNA isolated from diseased breast tissue removed from a 55-year-old Caucasian female during a unilateral extended simple mastectomy. Pathology indicated proliferative fibrocystic changes characterized by apocrine metaplasia, sclerosing adenosis, cyst formation, and ductal hyperplasia without atypia. Pathology for the associated tumor tissue indicated an invasive grade 4 mammary adenocarcinoma. Patient history included atrial tachycardia and a benign neoplasm. Family history included cardiovascular and cerebrovascular disease.
11	1717058	UCMCNOT02	Library was constructed using RNA isolated from mononuclear cells obtained from the umbilical cord blood of nine individuals.
12	1749964	STOMTUT02	Library was constructed using RNA isolated from stomach tumor tissue obtained from a 68-year-old Caucasian female during a partial gastrectomy. Pathology indicated a malignant lymphoma of diffuse large-cell type. Previous surgeries included cholecystectomy. Patient history included thalassemia. Family history included acute leukemia, atherosclerotic coronary artery disease, and malignant neoplasm of the esophagus and stomach.

WO 00/12703

PCT/US99/19616

TABLE 4 cont.

Polynucleotide SEQ ID NO:	Clone ID	Library	Library Description
13	1856357	PROSNOT18	Library was constructed using RNA isolated from diseased prostate tissue removed from a 58-year-old Caucasian male during a radical cystectomy, radical prostatectomy, and gastrectomy. Pathology indicated adenofibromatous hyperplasia; this tissue was associated with a grade 3 transitional cell carcinoma. Patient history included angina and emphysema. Family history included acute myocardial infarction, atherosclerotic coronary artery disease, and type II diabetes.
14	1871275	SKINBIT01	Library was constructed using RNA isolated from diseased skin tissue of the left lower leg. Patient history included erythema nodosum of the left lower leg.
15	2645806	OVARTUT04	Library was constructed using RNA isolated from ovarian tumor tissue removed from a 53-year-old Caucasian female during a total abdominal hysterectomy, removal of the fallopian tubes and ovaries, regional lymph node excision, and peritoneal tissue destruction. Pathology indicated grade 1 transitional cell carcinoma of the right ovary. The left ovary had a hemorrhagic corpus luteum. The uterus had multiple leiomyomas (1 submucosal, 11 intramural), and the endometrium was inactive. The cul-de-sac contained abundant histiocytes and rare clusters of mesothelial cells. Patient history included breast fibrosclerosis and chronic stomach ulcer. Family history included acute stomach ulcer with perforation, breast cancer, bladder cancer, rectal/anal cancer, benign hypertension, coronary angioplasty, and hyperlipidemia.
16	3437773	PENCNOT05	Library was constructed using RNA isolated from penis left corpus cavernosum tissue removed from a male.

Table 5

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Perkin-Elmer Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25: 3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad Sci. 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183: 63-98; and Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value= 1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLocks IMProved Searcher that matches a sequence against those in BLOCKS and PRINTS databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S and J.G. Henikoff, Nucl. Acid Res., 19:6565-72, 1991. J.G. Henikoff and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37: 417-424.	Score=1000 or greater; Ratio of Score/Strength = 0.75 or larger; and Probability value= 1.0E-3 or less
PFAM	A Hidden Markov Models-based application useful for protein family search.	Krogh, A. et al. (1994) J. Mol. Biol., 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322.	Score=10-50 bits, depending on individual protein families

Table 5 cont.

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25: 217-221.	Score= 4.0 or greater
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M. S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M. S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12: 431-439.	Score=5 or greater
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch et al. <u>supra</u> ; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

WO 00/12703

PCT/US99/19616

SEQUENCE LISTING

<110> INCYTE PHARMACEUTICALS, INC.

TANG, Y. Tom

LAL, Preeti

BANDMAN, Olga

YUE, Henry

CORLEY, Neil C.

GUEGLER, Karl J.

GORGONE, Gina A.

BAUGHN, Mariah R.

PATTERSON, Chandra

<120> PROTEIN TRANSPORT-ASSOCIATED MOLECULES

<130> PF-0577 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/098,206

<151> 1998-08-27

<160> 16

<170> PERL Program

<210> 1

<211> 480

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:012033CD1

<400> 1

Met	Arg	Phe	Val	Val	Ala	Leu	Val	Leu	Leu	Asn	Val	Ala	Ala	Ala
1				5				10						15
Gly	Ala	Val	Pro	Leu	Leu	Ala	Thr	Glu	Ser	Val	Lys	Gln	Glu	Glu
			20					25						30
Ala	Gly	Val	Arg	Pro	Ser	Ala	Gly	Asn	Val	Ser	Thr	His	Pro	Ser
			35					40						45
Leu	Ser	Gln	Arg	Pro	Gly	Gly	Ser	Thr	Lys	Ser	His	Pro	Glu	Pro
			50					55						60
Gln	Thr	Pro	Lys	Asp	Ser	Pro	Ser	Lys	Ser	Ser	Ala	Glu	Ala	Gln
			65					70						75
Thr	Pro	Glu	Asp	Thr	Pro	Asn	Lys	Ser	Gly	Ala	Glu	Ala	Lys	Thr
			80					85						90
Gln	Lys	Asp	Ser	Ser	Asn	Lys	Ser	Gly	Ala	Glu	Ala	Lys	Thr	Gln
			95					100						105
Lys	Gly	Ser	Thr	Ser	Lys	Ser	Gly	Ser	Glu	Ala	Gln	Thr	Thr	Lys
			110					115						120
Asp	Ser	Thr	Ser	Lys	Ser	His	Ser	Glu	Leu	Gln	Thr	Pro	Lys	Asp
			125					130						135
Ser	Thr	Gly	Lys	Ser	Gly	Ala	Glu	Ala	Gln	Thr	Pro	Glu	Asp	Ser
			140					145						150
Pro	Asn	Arg	Ser	Gly	Ala	Glu	Ala	Lys	Thr	Gln	Lys	Asp	Ser	Pro
			155					160						165

WO 00/12703

PCT/US99/19616

Ser	Lys	Ser	Gly	Ser	Glu	Ala	Gln	Thr	Thr	Lys	Asp	Val	Pro	Asn
				170					175					180
Lys	Ser	Gly	Ala	Asp	Gly	Gln	Thr	Pro	Lys	Asp	Gly	Ser	Ser	Lys
				185					190					195
Ser	Gly	Ala	Glu	Asp	Gln	Thr	Pro	Lys	Asp	Val	Pro	Asn	Lys	Ser
				200					205					210
Gly	Ala	Glu	Lys	Gln	Thr	Pro	Lys	Asp	Gly	Ser	Asn	Lys	Ser	Gly
				215					220					225
Ala	Glu	Glu	Gln	Gly	Pro	Ile	Asp	Gly	Pro	Ser	Lys	Ser	Gly	Ala
				230					235					240
Glu	Glu	Gln	Thr	Ser	Lys	Asp	Ser	Pro	Asn	Lys	Val	Val	Pro	Glu
				245					250					255
Gln	Pro	Ser	Arg	Lys	Asp	His	Ser	Lys	Pro	Ile	Ser	Asn	Pro	Ser
				260					265					270
Asp	Asn	Lys	Glu	Leu	Pro	Lys	Ala	Asp	Thr	Asn	Gln	Leu	Ala	Asp
				275					280					285
Lys	Gly	Lys	Leu	Ser	Pro	His	Ala	Phe	Lys	Thr	Glu	Ser	Gly	Glu
				290					295					300
Glu	Thr	Asp	Leu	Ile	Ser	Pro	Pro	Gln	Glu	Glu	Val	Lys	Ser	Ser
				305					310					315
Glu	Pro	Thr	Glu	Asp	Val	Glu	Pro	Lys	Glu	Ala	Glu	Asp	Asp	Asp
				320					325					330
Thr	Gly	Pro	Glu	Glu	Gly	Ser	Pro	Pro	Lys	Glu	Glu	Lys	Glu	Lys
				335					340					345
Met	Ser	Gly	Ser	Ala	Ser	Ser	Glu	Asn	Arg	Glu	Gly	Thr	Leu	Ser
				350					355					360
Asp	Ser	Thr	Gly	Ser	Glu	Lys	Asp	Asp	Leu	Tyr	Pro	Asn	Gly	Ser
				365					370					375
Gly	Asn	Gly	Ser	Ala	Glu	Ser	Ser	His	Phe	Phe	Ala	Tyr	Leu	Val
				380					385					390
Thr	Ala	Ala	Ile	Leu	Val	Ala	Val	Leu	Tyr	Ile	Ala	His	His	Asn
				395					400					405
Lys	Arg	Lys	Ile	Ile	Ala	Phe	Val	Leu	Glu	Gly	Lys	Arg	Ser	Lys
				410					415					420
Val	Thr	Arg	Arg	Pro	Lys	Ala	Ser	Asp	Tyr	Gln	Arg	Leu	Asp	Gln
				425					430					435
Lys	Tyr	Val	Leu	Ile	Leu	Asn	Val	Phe	Pro	Ala	Pro	Pro	Lys	Arg
				440					445					450
Ser	Phe	Leu	Pro	Gln	Val	Leu	Thr	Glu	Trp	Tyr	Ile	Pro	Leu	Glu
				455					460					465
Lys	Asp	Glu	Arg	His	Gln	Trp	Ile	Val	Leu	Leu	Ser	Phe	Gln	Leu
				470					475					480

<210> 2

<211> 140

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1209687CD1

<400> 2

Met	Ala	Ser	Val	Asp	Phe	Lys	Thr	Tyr	Val	Asp	Gln	Ala	Cys	Arg
1				5				10					15	

WO 00/12703

PCT/US99/19616

Ala	Ala	Glu	Glu	Phe	Val	Asn	Val	Tyr	Tyr	Thr	Thr	Met	Asp	Lys
				20					25					30
Arg	Arg	Arg	Leu	Leu	Ser	Arg	Leu	Tyr	Met	Gly	Thr	Ala	Thr	Leu
			35						40					45
Val	Trp	Asn	Gly	Asn	Ala	Val	Ser	Gly	Gln	Glu	Ser	Leu	Ser	Glu
			50						55					60
Phe	Phe	Glu	Met	Leu	Pro	Ser	Ser	Glu	Phe	Gln	Ile	Ser	Val	Val
			65						70					75
Asp	Cys	Gln	Pro	Val	His	Asp	Glu	Ala	Thr	Pro	Ser	Gln	Thr	Thr
			80						85					90
Val	Leu	Val	Val	Ile	Cys	Gly	Ser	Val	Lys	Phe	Glu	Gly	Asn	Lys
			95						100					105
Gln	Arg	Asp	Phe	Asn	Gln	Asn	Phe	Ile	Leu	Thr	Ala	Gln	Ala	Ser
			110						115					120
Pro	Ser	Asn	Thr	Val	Trp	Lys	Ile	Ala	Ser	Asp	Cys	Phe	Arg	Phe
			125						130					135
Gln	Asp	Trp	Ala	Ser										
				140										

<210> 3

<211> 519

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1717058CD1

<400> 3

Met	Ala	Ala	Glu	Arg	Glu	Pro	Pro	Pro	Leu	Gly	Asp	Gly	Lys	Pro
1				5					10					15
Thr	Asp	Phe	Glu	Asp	Leu	Glu	Asp	Gly	Glu	Asp	Leu	Phe	Thr	Ser
			20						25					30
Thr	Val	Ser	Thr	Leu	Glu	Ser	Ser	Pro	Ser	Ser	Pro	Glu	Pro	Ala
			35						40					45
Ser	Leu	Pro	Ala	Glu	Asp	Ile	Ser	Ala	Asn	Ser	Asn	Gly	Pro	Lys
			50						55					60
Pro	Thr	Glu	Val	Val	Leu	Asp	Asp	Asp	Arg	Glu	Asp	Leu	Phe	Ala
			65						70					75
Glu	Ala	Thr	Glu	Glu	Val	Ser	Leu	Asp	Ser	Pro	Glu	Arg	Glu	Pro
			80						85					90
Ile	Leu	Ser	Ser	Glu	Pro	Ser	Pro	Ala	Val	Thr	Pro	Val	Thr	Pro
			95						100					105
Thr	Thr	Leu	Ile	Ala	Pro	Arg	Ile	Glu	Ser	Lys	Ser	Met	Ser	Ala
			110						115					120
Pro	Val	Ile	Phe	Asp	Arg	Ser	Arg	Glu	Glu	Ile	Glu	Glu	Glu	Ala
			125						130					135
Asn	Gly	Asp	Ile	Phe	Asp	Ile	Glu	Ile	Gly	Val	Ser	Asp	Pro	Glu
			140						145					150
Lys	Val	Gly	Asp	Gly	Met	Asn	Ala	Tyr	Met	Ala	Tyr	Arg	Val	Thr
			155						160					165
Thr	Lys	Thr	Ser	Leu	Ser	Met	Phe	Ser	Lys	Ser	Glu	Phe	Ser	Val
			170						175					180
Lys	Arg	Arg	Phe	Ser	Asp	Phe	Leu	Gly	Leu	His	Ser	Lys	Leu	Ala
			185						190					195

WO 00/12703

PCT/US99/19616

Ser	Lys	Tyr	Leu	His	Val	Gly	Tyr	Ile	Val	Pro	Pro	Ala	Pro	Glu	200	205	210
Lys	Ser	Ile	Val	Gly	Met	Thr	Lys	Val	Lys	Val	Gly	Lys	Glu	Asp	215	220	225
Ser	Ser	Ser	Thr	Glu	Phe	Val	Glu	Lys	Arg	Arg	Ala	Ala	Leu	Glu	230	235	240
Arg	Tyr	Leu	Gln	Arg	Thr	Val	Lys	His	Pro	Thr	Leu	Leu	Gln	Asp	245	250	255
Pro	Asp	Leu	Arg	Gln	Phe	Leu	Glu	Ser	Ser	Glu	Leu	Pro	Arg	Ala	260	265	270
Val	Asn	Thr	Gln	Ala	Leu	Ser	Gly	Ala	Gly	Ile	Leu	Arg	Met	Val	275	280	285
Asn	Lys	Ala	Ala	Asp	Ala	Val	Asn	Lys	Met	Thr	Ile	Lys	Met	Asn	290	295	300
Glu	Ser	Asp	Ala	Trp	Phe	Glu	Glu	Lys	Gln	Gln	Gln	Phe	Glu	Asn	305	310	315
Leu	Asp	Gln	Gln	Leu	Arg	Lys	Leu	His	Val	Ser	Val	Glu	Ala	Leu	320	325	330
Val	Cys	His	Arg	Lys	Glu	Leu	Ser	Ala	Asn	Thr	Ala	Ala	Phe	Ala	335	340	345
Lys	Ser	Ala	Ala	Met	Leu	Gly	Asn	Ser	Glu	Asp	His	Thr	Ala	Leu	350	355	360
Ser	Arg	Ala	Leu	Ser	Gln	Leu	Ala	Glu	Val	Glu	Glu	Lys	Ile	Asp	365	370	375
Gln	Leu	His	Gln	Glu	Gln	Ala	Phe	Ala	Asp	Phe	Tyr	Met	Phe	Ser	380	385	390
Glu	Leu	Leu	Ser	Asp	Tyr	Ile	Arg	Leu	Ile	Ala	Ala	Val	Lys	Gly	395	400	405
Val	Phe	Asp	His	Arg	Met	Lys	Cys	Trp	Gln	Lys	Trp	Glu	Asp	Ala	410	415	420
Gln	Ile	Thr	Leu	Leu	Lys	Lys	Arg	Glu	Ala	Glu	Ala	Lys	Met	Met	425	430	435
Val	Ala	Asn	Lys	Pro	Asp	Lys	Ile	Gln	Gln	Ala	Lys	Asn	Glu	Ile	440	445	450
Arg	Glu	Trp	Glu	Ala	Lys	Val	Gln	Gln	Gly	Glu	Arg	Asp	Phe	Glu	455	460	465
Gln	Ile	Ser	Lys	Thr	Ile	Arg	Lys	Glu	Val	Gly	Arg	Phe	Glu	Lys	470	475	480
Glu	Arg	Val	Lys	Asp	Phe	Lys	Thr	Val	Ile	Ile	Lys	Tyr	Leu	Glu	485	490	495
Ser	Leu	Val	Gln	Thr	Gln	Gln	Gln	Leu	Ile	Lys	Tyr	Trp	Glu	Ala	500	505	510
Phe	Leu	Pro	Glu	Ala	Lys	Ala	Ile	Ala							515		

<210> 4

<211> 613

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1749964CD1

WO 00/12703

PCT/US99/19616

<400> 4

Met	Ala	Ala	Thr	Ala	Val	Ala	Ala	Ala	Val	Ala	Gly	Thr	Glu	Ser
1				5					10					15
Ala	Gln	Gly	Pro	Pro	Gly	Pro	Ala	Ala	Ser	Leu	Glu	Leu	Trp	Leu
				20					25					30
Asn	Lys	Ala	Thr	Asp	Pro	Ser	Met	Ser	Glu	Gln	Asp	Trp	Ser	Ala
				35					40					45
Ile	Gln	Asn	Phe	Cys	Glu	Gln	Val	Asn	Thr	Asp	Pro	Asn	Gly	Pro
				50					55					60
Thr	His	Ala	Pro	Trp	Leu	Leu	Ala	His	Lys	Ile	Gln	Ser	Pro	Gln
				65					70					75
Glu	Lys	Glu	Ala	Leu	Tyr	Ala	Leu	Thr	Val	Leu	Glu	Met	Cys	Met
				80					85					90
Asn	His	Cys	Gly	Glu	Lys	Phe	His	Ser	Glu	Val	Ala	Lys	Phe	Arg
				95					100					105
Phe	Leu	Asn	Glu	Leu	Ile	Lys	Val	Leu	Ser	Pro	Lys	Tyr	Leu	Gly
				110					115					120
Ser	Trp	Ala	Thr	Gly	Lys	Val	Lys	Gly	Arg	Val	Ile	Glu	Ile	Leu
				125					130					135
Phe	Ser	Trp	Thr	Val	Trp	Phe	Pro	Glu	Asp	Ile	Lys	Ile	Arg	Asp
				140					145					150
Ala	Tyr	Gln	Met	Leu	Lys	Lys	Gln	Gly	Ile	Ile	Lys	Gln	Asp	Pro
				155					160					165
Lys	Leu	Pro	Val	Asp	Lys	Ile	Leu	Pro	Pro	Pro	Ser	Pro	Trp	Pro
				170					175					180
Lys	Ser	Ser	Ile	Phe	Asp	Ala	Asp	Glu	Glu	Lys	Ser	Lys	Leu	Leu
				185					190					195
Thr	Arg	Leu	Leu	Lys	Ser	Asn	His	Pro	Glu	Asp	Leu	Gln	Ala	Ala
				200					205					210
Asn	Arg	Leu	Ile	Lys	Asn	Leu	Val	Lys	Glu	Glu	Gln	Glu	Lys	Ser
				215					220					225
Glu	Lys	Val	Ser	Lys	Arg	Val	Ser	Ala	Val	Glu	Glu	Val	Arg	Ser
				230					235					240
His	Val	Lys	Val	Leu	Gln	Glu	Met	Leu	Ser	Met	Tyr	Arg	Arg	Pro
				245					250					255
Gly	Gln	Ala	Pro	Pro	Asp	Gln	Glu	Ala	Leu	Gln	Val	Val	Tyr	Glu
				260					265					270
Arg	Cys	Glu	Lys	Leu	Arg	Pro	Thr	Leu	Phe	Arg	Leu	Ala	Ser	Asp
				275					280					285
Thr	Thr	Asp	Asp	Asp	Asp	Ala	Leu	Ala	Glu	Ile	Leu	Gln	Ala	Asn
				290					295					300
Asp	Leu	Leu	Thr	Gln	Gly	Val	Leu	Leu	Tyr	Lys	Gln	Val	Met	Glu
				305					310					315
Gly	Arg	Val	Thr	Phe	Gly	Asn	Arg	Val	Thr	Ser	Ser	Leu	Gly	Asp
				320					325					330
Ile	Pro	Val	Ser	Arg	Val	Phe	Gln	Asn	Pro	Ala	Gly	Cys	Met	Lys
				335					340					345
Thr	Cys	Pro	Leu	Ile	Asp	Leu	Glu	Val	Asp	Asn	Gly	Pro	Ala	Gln
				350					355					360
Met	Gly	Thr	Val	Val	Pro	Ser	Leu	Leu	His	Gln	Asp	Leu	Ala	Ala
				365					370					375
Leu	Gly	Ile	Ser	Asp	Ala	Pro	Val	Thr	Gly	Met	Val	Ser	Gly	Gln
				380					385					390
Asn	Cys	Cys	Glu	Glu	Lys	Arg	Asn	Pro	Ser	Ser	Ser	Thr	Leu	Pro
				395					400					405
Gly	Gly	Gly	Val	Gln	Asn	Pro	Ser	Ala	Asp	Arg	Asn	Leu	Leu	Asp
				410					415					420

WO 00/12703

PCT/US99/19616

Leu	Leu	Ser	Ala	Gln	Pro	Ala	Pro	Cys	Pro	Leu	Asn	Tyr	Val	Ser	
				425					430					435	
Gln	Lys	Ser	Val	Pro	Lys	Glu	Val	Pro	Pro	Gly	Thr	Lys	Ser	Ser	
				440					445					450	
Pro	Gly	Trp	Ser	Trp	Glu	Ala	Gly	Pro	Leu	Ala	Pro	Ser	Pro	Ser	
				455					460					465	
Ser	Gln	Asn	Thr	Pro	Leu	Ala	Gln	Val	Phe	Val	Pro	Leu	Glu	Ser	
				470					475					480	
Val	Lys	Pro	Ser	Ser	Leu	Pro	Pro	Leu	Ile	Val	Tyr	Asp	Arg	Asn	
				485					490					495	
Gly	Phe	Arg	Ile	Leu	Leu	His	Phe	Ser	Gln	Thr	Gly	Ala	Pro	Gly	
				500					505					510	
His	Pro	Glu	Val	Gln	Val	Leu	Leu	Leu	Thr	Met	Met	Ser	Thr	Ala	
				515					520					525	
Pro	Gln	Pro	Val	Trp	Asp	Ile	Met	Phe	Gln	Val	Ala	Val	Pro	Lys	
				530					535					540	
Ser	Met	Arg	Val	Lys	Leu	Gln	Pro	Ala	Ser	Ser	Ser	Lys	Leu	Pro	
				545					550					555	
Ala	Phe	Ser	Pro	Leu	Met	Pro	Pro	Ala	Val	Ile	Ser	Gln	Met	Leu	
				560					565					570	
Leu	Leu	Asp	Asn	Pro	His	Lys	Glu	Pro	Ile	Arg	Leu	Arg	Tyr	Lys	
				575					580					585	
Leu	Thr	Phe	Asn	Gln	Gly	Gly	Gln	Pro	Phe	Ser	Glu	Val	Gly	Glu	
				590					595					600	
Val	Lys	Asp	Phe	Pro	Asp	Leu	Ala	Val	Leu	Gly	Ala	Ala			
				605					610						

<210> 5

<211> 719

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1856357CD1

<400> 5

Met	Ser	Val	Asp	Lys	Ala	Glu	Leu	Cys	Gly	Ser	Leu	Leu	Thr	Trp	
1				5					10					15	
Leu	Gln	Thr	Phe	His	Val	Pro	Ser	Pro	Cys	Ala	Ser	Pro	Gln	Asp	
				20					25					30	
Leu	Ser	Ser	Gly	Leu	Ala	Val	Ala	Tyr	Val	Leu	Asn	Gln	Ile	Asp	
				35					40					45	
Pro	Ser	Trp	Phe	Asn	Glu	Ala	Trp	Leu	Gln	Gly	Ile	Ser	Glu	Asp	
				50					55					60	
Pro	Gly	Pro	Asn	Trp	Lys	Leu	Lys	Val	Ser	Asn	Leu	Lys	Met	Val	
				65					70					75	
Leu	Arg	Ser	Leu	Val	Glu	Tyr	Ser	Gln	Asp	Val	Leu	Ala	His	Pro	
				80					85					90	
Val	Ser	Glu	Glu	His	Leu	Pro	Asp	Val	Ser	Leu	Ile	Gly	Glu	Phe	
				95					100					105	
Ser	Asp	Pro	Ala	Glu	Leu	Gly	Lys	Leu	Leu	Gln	Leu	Val	Leu	Gly	
				110					115					120	
Cys	Ala	Ile	Ser	Cys	Glu	Lys	Lys	Gln	Asp	His	Ile	Gln	Arg	Ile	
				125					130					135	

WO 00/12703

PCT/US99/19616

Met	Thr	Leu	Glu	Glu	Ser	Val	Gln	His	Val	Val	Met	Glu	Ala	Ile
				140					145					150
Gln	Glu	Leu	Met	Thr	Lys	Asp	Thr	Pro	Asp	Ser	Leu	Ser	Pro	Glu
				155					160					165
Thr	Tyr	Gly	Asn	Phe	Asp	Ser	Gln	Ser	Arg	Arg	Tyr	Tyr	Phe	Leu
				170					175					180
Ser	Glu	Glu	Ala	Glu	Glu	Gly	Asp	Glu	Leu	Gln	Gln	Arg	Cys	Leu
				185					190					195
Asp	Leu	Glu	Arg	Gln	Leu	Met	Leu	Leu	Ser	Glu	Glu	Lys	Gln	Ser
				200					205					210
Leu	Ala	Gln	Glu	Asn	Ala	Gly	Leu	Arg	Glu	Arg	Met	Gly	Arg	Pro
				215					220					225
Glu	Gly	Glu	Gly	Thr	Pro	Gly	Leu	Thr	Ala	Lys	Lys	Leu	Leu	Leu
				230					235					240
Leu	Gln	Ser	Gln	Leu	Glu	Gln	Leu	Gln	Glu	Glu	Asn	Phe	Arg	Leu
				245					250					255
Glu	Ser	Gly	Arg	Glu	Asp	Glu	Arg	Leu	Arg	Cys	Ala	Glu	Leu	Glu
				260					265					270
Arg	Glu	Val	Ala	Glu	Leu	Gln	His	Arg	Asn	Gln	Ala	Leu	Thr	Ser
				275					280					285
Leu	Ala	Gln	Glu	Ala	Gln	Ala	Leu	Lys	Asp	Glu	Met	Asp	Glu	Leu
				290					295					300
Arg	Gln	Ser	Ser	Glu	Arg	Ala	Gly	Gln	Leu	Glu	Ala	Thr	Leu	Thr
				305					310					315
Ser	Cys	Arg	Arg	Arg	Leu	Gly	Glu	Leu	Arg	Glu	Leu	Arg	Arg	Gln
				320					325					330
Val	Arg	Gln	Leu	Glu	Glu	Arg	Asn	Ala	Gly	His	Ala	Glu	Arg	Thr
				335					340					345
Arg	Gln	Leu	Glu	Asp	Glu	Leu	Arg	Arg	Ala	Gly	Ser	Leu	Arg	Ala
				350					355					360
Gln	Leu	Glu	Ala	Gln	Arg	Arg	Gln	Val	Gln	Glu	Leu	Gln	Gly	Gln
				365					370					375
Arg	Gln	Glu	Glu	Ala	Met	Lys	Ala	Glu	Lys	Trp	Leu	Phe	Glu	Cys
				380					385					390
Arg	Asn	Leu	Glu	Glu	Lys	Tyr	Glu	Ser	Val	Thr	Lys	Glu	Lys	Glu
				395					400					405
Arg	Leu	Leu	Ala	Glu	Arg	Asp	Ser	Leu	Arg	Glu	Ala	Asn	Glu	Glu
				410					415					420
Leu	Arg	Cys	Ala	Gln	Leu	Gln	Pro	Arg	Gly	Leu	Thr	Gln	Ala	Asp
				425					430					435
Pro	Ser	Leu	Asp	Pro	Thr	Ser	Thr	Pro	Val	Asp	Asn	Leu	Ala	Ala
				440					445					450
Glu	Ile	Leu	Pro	Ala	Glu	Leu	Arg	Glu	Thr	Leu	Leu	Arg	Leu	Gln
				455					460					465
Leu	Glu	Asn	Lys	Arg	Leu	Cys	Arg	Gln	Glu	Ala	Ala	Asp	Arg	Glu
				470					475					480
Arg	Gln	Glu	Glu	Leu	Gln	Arg	His	Leu	Glu	Asp	Ala	Asn	Arg	Ala
				485					490					495
Arg	His	Gly	Leu	Glu	Thr	Gln	His	Arg	Leu	Asn	Gln	Gln	Gln	Leu
				500					505					510
Ser	Glu	Leu	Arg	Ala	Gln	Val	Glu	Asp	Leu	Gln	Lys	Ala	Leu	Gln
				515					520					525
Glu	Gln	Gly	Gly	Lys	Thr	Glu	Asp	Ala	Ile	Ser	Ile	Leu	Leu	Lys
				530					535					540
Arg	Lys	Leu	Glu	Glu	His	Leu	Gln	Lys	Leu	His	Glu	Ala	Asp	Leu
				545					550					555
Glu	Leu	Gln	Arg	Lys	Arg	Glu	Tyr	Ile	Glu	Glu	Leu	Glu	Pro	Pro

WO 00/12703

PCT/US99/19616

	560		565		570
Thr Asp Ser Ser	Thr Ala Arg Arg Ile	Glu Glu Leu Gln His Asn			
	575		580		585
Leu Gln Lys Lys	Asp Ala Asp Leu Arg	Ala Met Glu Glu Arg Tyr			
	590		595		600
Arg Arg Tyr Val	Asp Lys Ala Arg Met	Val Met Gln Thr Met Glu			
	605		610		615
Pro Lys Gln Arg	Pro Ala Ala Gly Ala	Pro Pro Glu Leu His Ser			
	620		625		630
Leu Arg Thr Gln	Leu Arg Glu Arg Asp	Val Arg Ile Arg His Leu			
	635		640		645
Glu Met Asp Phe	Glu Lys Ser Arg Ser	Gln Arg Glu Gln Glu Glu			
	650		655		660
Lys Leu Leu Ile	Ser Ala Trp Tyr Asn	Met Gly Met Ala Leu Gln			
	665		670		675
Gln Arg Ala Gly	Glu Glu Arg Ala Pro	Ala His Ala Gln Ser Phe			
	680		685		690
Leu Ala Gln Gln	Arg Leu Ala Thr Asn	Ser Arg Arg Gly Pro Leu			
	695		700		705
Gly Arg Leu Ala	Ser Leu Asn Leu Arg	Pro Thr Asp Lys His			
	710		715		

<210> 6

<211> 175

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1871275CD1

<400> 6

Met Gly Ile Leu Leu Gly Leu Leu Leu Leu Gly His Leu Thr Val		
1	5	10 15
Asp Thr Tyr Gly Arg Pro Ile Leu Glu Val Pro Glu Ser Val Thr		
	20	25 30
Gly Pro Trp Lys Gly Asp Val Asn Leu Pro Cys Thr Tyr Asp Pro		
	35	40 45
Leu Gln Gly Tyr Thr Gln Val Leu Val Lys Trp Leu Val Gln Arg		
	50	55 60
Gly Ser Asp Pro Val Thr Ile Phe Leu Arg Asp Ser Ser Gly Asp		
	65	70 75
His Ile Gln Gln Ala Lys Tyr Gln Gly Arg Leu His Val Ser His		
	80	85 90
Lys Val Pro Gly Asp Val Ser Leu Gln Leu Ser Thr Leu Glu Met		
	95	100 105
Asp Asp Arg Ser His Tyr Thr Cys Glu Val Thr Trp Gln Thr Pro		
	110	115 120
Asp Gly Asn Gln Val Val Arg Asp Lys Ile Thr Glu Leu Arg Val		
	125	130 135
Gln Lys His Ser Ser Lys Leu Leu Lys Thr Lys Thr Glu Ala Pro		
	140	145 150
Thr Thr Met Thr Tyr Pro Leu Lys Ala Thr Ser Thr Val Lys Gln		
	155	160 165
Ser Trp Asp Trp Thr Thr Asp Met Asp Gly		
	170	175

WO 00/12703

PCT/US99/19616

<210> 7
 <211> 142
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No:2645806CD1

<400> 7
 Met Ala Thr Ser Leu Asp Phe Lys Thr Tyr Val Asp Gln Ala Cys
 1 5 10 15
 Arg Ala Ala Glu Glu Phe Val Asn Ile Tyr Tyr Glu Thr Met Asp
 20 25 30
 Lys Arg Arg Arg Ala Leu Thr Arg Leu Tyr Leu Asp Lys Ala Thr
 35 40 45
 Leu Ile Trp Asn Gly Asn Ala Val Ser Gly Leu Asp Ala Leu Asn
 50 55 60
 Asn Phe Phe Asp Thr Leu Pro Ser Ser Glu Phe Gln Val Asn Met
 65 70 75
 Leu Asp Cys Gln Pro Val His Glu Gln Ala Thr Gln Ser Gln Thr
 80 85 90
 Thr Val Leu Val Val Thr Ser Gly Thr Val Lys Phe Asp Gly Asn
 95 100 105
 Lys Gln His Phe Phe Asn Gln Asn Phe Leu Leu Thr Ala Gln Ser
 110 115 120
 Thr Pro Asn Asn Thr Val Trp Lys Ile Ala Ser Asp Cys Phe Arg
 125 130 135
 Phe Gln Asp Trp Ser Ser Ser
 140

<210> 8
 <211> 248
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No:3437773CD1

<400> 8
 Met Ser Val Ser Leu Pro Leu Thr Val Met Val Arg Glu Arg Asp
 1 5 10 15
 Trp Ile Gly Ile His Leu Phe Ser Leu Tyr Leu Ser Leu Pro Val
 20 25 30
 Gly Ile Pro Asp Phe Gly Ser Ile Trp Ser Asp Phe Leu Phe Lys
 35 40 45
 Phe Leu Val Ile Gly Ser Ala Gly Thr Gly Lys Ser Cys Leu Leu
 50 55 60
 His Gln Phe Ile Glu Asn Lys Phe Lys Gln Asp Ser Asn His Thr
 65 70 75
 Ile Gly Val Glu Phe Gly Ser Arg Val Val Asn Val Gly Gly Lys
 80 85 90

WO 00/12703

PCT/US99/19616

Thr	Val	Lys	Leu	Gln	Ile	Trp	Asp	Thr	Ala	Gly	Gln	Glu	Arg	Phe	
				95					100					105	
Arg	Ser	Val	Thr	Arg	Ser	Tyr	Tyr	Arg	Gly	Ala	Ala	Gly	Ala	Leu	
				110					115					120	
Leu	Val	Tyr	Asp	Ile	Thr	Ser	Arg	Glu	Thr	Tyr	Asn	Ser	Leu	Ala	
				125					130					135	
Ala	Trp	Leu	Thr	Asp	Ala	Arg	Thr	Leu	Ala	Ser	Pro	Asn	Ile	Val	
				140					145					150	
Val	Ile	Leu	Cys	Gly	Asn	Lys	Lys	Asp	Leu	Asp	Pro	Glu	Arg	Glu	
				155					160					165	
Val	Thr	Phe	Leu	Glu	Ala	Ser	Arg	Phe	Ala	Gln	Glu	Asn	Glu	Leu	
				170					175					180	
Met	Phe	Leu	Glu	Thr	Ser	Ala	Leu	Thr	Gly	Glu	Asn	Val	Glu	Glu	
				185					190					195	
Ala	Phe	Leu	Lys	Cys	Ala	Arg	Thr	Ile	Leu	Asn	Lys	Ile	Asp	Ser	
				200					205					210	
Gly	Glu	Leu	Asp	Pro	Glu	Arg	Met	Gly	Ser	Gly	Ile	Gln	Tyr	Gly	
				215					220					225	
Asp	Ala	Ser	Leu	Arg	Gln	Leu	Arg	Gln	Pro	Arg	Ser	Ala	Gln	Ala	
				230					235					240	
Val	Ala	Pro	Gln	Pro	Cys	Gly	Cys								
				245											

<210> 9

<211> 1630

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:012033CB1

<400> 9

```

cgctatccga gcaggatgcg gttcgtgggt gccttggtcc tctgaacgt cgcagcggcg 60
ggagccgtgc cgctcttggc caccgaaagc gtcaagcaag aagaagctgg agtacggcct 120
tctgcaggaa acgtctccac ccaccccagc ttgagccaac ggcctggagg ctctaccaag 180
tcgcatccgg agccgcagac tccaaaagac agccctagca agtcgagtgc ggaggcgcag 240
accccagaag acacccccaa caagtcgggt gcggaggcaa agacccaaaa agacagctcc 300
aacaagtcgg gtgcggaggc aaagacccaa aaaggcagca ctagcaagtc gggttcggag 360
gcgagacca caaaagacag cactagtaag tcgcattcgg agtcgcagac tccaaaagac 420
agcactggca aatcgggtgc ggaggcgcag accccagaag acagcccaa caggtcgggt 480
gcggaggcaa agacccaaaa agacagccct agcaagtcag gttcggaggc gcagaccaca 540
aaagatgtcc ctaataagtc ggggtgcggac ggccagaccc caaaagacgg ctccagcaag 600
tcgggtgcgg aggatcagac cccaaaagac gtccctaaca agtcgggtgc ggagaagcag 660
actccaaaag acggctctaa caagtcgggt gcagaggagc agggcccaat agacgggccc 720
agcaagtcgg gtgcggagga gcagacctca aaagacagcc ctaacaaggt ggttccagag 780
cagccttccc ggaaagacca ttccaagccc atctccaacc cttctgataa caaggagctc 840
cccaaggctg acacaaacca gcttgctgac aaagggaagc tttctcctca tgctttcaaa 900
accgaatctg gggaggaaac tgacctcatt tctccccgc aggaggaagt taagtcttca 960
gagcctactg aggatgtgga gcccaaagag gctgaagatg atgatacagg acccgaggag 1020
ggctcaccgc ccaaagaaga gaaagaaaag atgtccgggt ctgcctccag tgagaaccgt 1080
gaagggacac tttcggattc cacgggtagc gagaaggatg acctttatcc gaacggttct 1140
ggaaatggca gcgcggagag cagccacttc tttgcatatc tggtgactgc agccattctt 1200
gtggctgtcc tctatatcgc tcatcacaac aagcggaaga tcattgcttt tgcctggaa 1260

```


WO 00/12703

PCT/US99/19616

```

ggaaaaagat ctaaagtcac ccggcggcca aaggccagtg actaccaacg tttggaccag 1320
aagtatgtct taattctgaa tgttttccct gcacctccta aaagatcttt tctcccccaa 1380
gtcctaacag aatgggtatat tcctctggaa aaagatgaac gtcaccaatg gattgtgctg 1440
ctctcgtttc agctttgatt tttttgtcct tgagaacctt gtcctccctg ctgatttgtt 1500
tctaaatcaa aagaaatgaa gaaaaaagta ctgtgacctg agagacaccc tcctctagaa 1560
tttagtggcg ggtctgggct ggcagaggta gggggctgct ttgggctttg cacctgcact 1620
ttggtgacat                                     1630

```

<210> 10

<211> 830

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1209687CB1

<400> 10

```

tgaactttgg cattcacgtg gcttctcttc aaccttactt ccctgcagcc cctggttccc 60
caaggcagag gaaataccct ggtggagccc tccttccata gaaccagaga tggcatctgt 120
ggatttcaag acctatgtgg atcaggcctg cagagctgct gaggagtttg tcaatgtcta 180
ctacaccacc atggataagc ggcggcggtt gctgtcccgc ctgtacatgg gcacagccac 240
cctgggtctgg aatggcaatg ctgtttcagg acaagaatcc ttgagtgagt tttttgaaat 300
gttgccttcc agcgagtacc aaatcagcgt ggtagactgc cagcctgttc atgatgaagc 360
cacaccaagc cagaccacgg tccttgttgt catctgtgga tcagtgaagt ttgaggggaa 420
caaacaacgg gacttcaacc agaacttcat cctgaccgcc caggcctcac ccagcaacac 480
agtgtggaag atcgcaagtg actgcttccg cttccaggac tgggccagct agtgggggtg 540
gcagaggtct ctttgcttca ttcagcccta gctctgtaga gaaatgcaaa cctcgactct 600
caaggatgtg aggaacacaa gttcatttct gttgttgctg agacactgca gactccactg 660
tgccgaggtt gaactctttt ttgttgctca agttctagga gtccctttcc tgaatatata 720
cttgtttgtc atagtcttct tttcaaagta gtaaactttt ctatttttct acttgcccag 780
tagagactct gattctggaa attctgacaa ataatttaat aatacacatg 830

```

<210> 11

<211> 2025

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1717058CB1

<400> 11

```

gtgagcgaag atggcggccg agagggaacc tcctccgctg ggggacggga agcccaccga 60
ctttgaggat ctggaggacg gagaggacct gttcaccagc actgtctcca ccctagagtc 120
aagtccatca tctccagaac cagctagtct tcctgcagaa gatattagtg caaactccaa 180
tggcccaaaa cccacagaag ttgtattaga tgatgacaga gaagatcttt ttgcagaagc 240
cacagaagaa gtttcttttg acagccctga aagggaacct atcctatcct cggaaccttc 300
tcctgcagtc acacctgtca ctectactac actcattgct cctagaattg aatcaaagag 360
tatgtctgct cccgtgatct ttgatagatc cagggaagag attgaagaag aagcaaattg 420
agacattttt gacatagaaa ttggtgtatc agatccagaa aaagttggtg atggcatgaa 480
tgcctatatg gcatatagag taacaacaaa gacatctctt tccatgttca gtaagagtga 540
attttcagtg aaaagaagat tcagcgactt tcttggtttg cacagcaaat tagcaagcaa 600
atatttacat gttgggtata ttgtgccacc agctccagaa aagagtatag tagggatgac 660
caagggtcaa gtgggtaaag aagactcatc atccactgag tttgtagaaa aacggagagc 720

```


WO 00/12703

PCT/US99/19616

```

agctcttgaa aggtatcttc aaagaacagt aaaacatcca actttactac aggatcctga 780
tttaaggcag ttcttggaag gttcagagct gcctagagca gttaatacac aggctctgag 840
tgagcagga atattgagga tgggtgaacaa ggctgccgac gctgtcaaca aaatgacaat 900
caagatgaat gaatcggatg catggtttga agaaaagcag cagcaatttg agaatctgga 960
tcagcaactt aggaaacttc atgtcagtggt tgaagccttg gtctgtcata gaaaagaact 1020
ttcagccaac acagctgcct ttgctaaaag tgctgccatg ttaggtaatt ctgaggatca 1080
tactgcttta tctagagctt tgtctcagct tgcagagggt gaggagaaga tagaccagtt 1140
acatcaagaa caagcttttg ctgactttta tatgttttca gaactactta gtgactacat 1200
tcgtcttatt gctgcagtgga aagggtgtgt tgacctcga atgaagtgtt ggcagaaatg 1260
ggaagatgct caaattactt tgctcaaaaa acgtgaagct gaagcaaaaa tgatgggtgc 1320
taacaaacca gataaaatac agcaagctaa aaatgaaata agagagtggg aggcgaaagt 1380
gcaacaaggg gaaagagatt ttgaacagat atctaaaacg attcgaaaag aagtgggaag 1440
atgtgagaaa gaacgagtga aggattttta aaccgttatc atcaagtact tagaatcact 1500
agttcaaaca caacaacagc tgataaaaata ctgggaagca ttcctacctg aagccaaagc 1560
cattgcctag caataagatt gttgccgtta agaagacctt ggatgttgtt ccagttatgc 1620
tggtattccac agtgaaatca tttaaaacca tctaaataaa ccactatata ttttatgaat 1680
tacatgtggt tttatataca cacacacaca cacacacaca ctctgacatt ttattacaag 1740
ctgcatgtcc tgacctctt tgaattaagt ggactgtggc atgacattct gcaatacttt 1800
gctgaattga acactattgt gtcttaaata cttgcactaa atagtgcact gcaagaccag 1860
aaaattttac aatatttttt ctttacaata tgttctgtag tatgtttacc ctctttatga 1920
agtgaattac caatgctttg aataatgttc acttatacat tcctgtacag aaattacgat 1980
tttgtgatta cagtaataaa atgatattcc ttgtgaaaaa aaaaa 2025

```

<210> 12

<211> 3465

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1749964CB1

<400> 12

```

acggccagtg caagctaaaa ttaaccctca ctaaaggga taagcttgcg ccgcggcgctc 60
ggggctggag cgatggcggc gaccgcggtg gcggcggctg tggcggaac cgagtcggcc 120
cagggtcccc cgggccccgc agcgtcgtg gagctgtggc tgaacaaagc cacagacca 180
agcatgtcgg aacaggattg gtcagctatc cagaatttct gtgagcaggt gaacactgac 240
cccaatggcc ccacacatgc gccctggcta ctggcccaca agatccagtc tccgcaagag 300
aaggaagctc tttatgcctt aacgggtgctg gagatgtgca tgaaccactg tggggagaag 360
ttccacagcg aggtggccaa atttcgtttc ctgaacgaac tgatcaaagt gttgtcccca 420
aagtacctgg ggtcctgggc cacaggaaaa gttaaaggaa gagtcattga aatactcttc 480
agttggacag tctggtttcc ggaagacatc aagattcgag acgcttatca gatgctgaag 540
aaacaaggaa ttataaaaca agaccctaaa ctaccagtgg ataaaatctt acccccacca 600
tctccctggc ccaagagctc catctttgat gctgatgaag aaaagtccaa gcttctgaca 660
aggcttctaa agagcaacca ccccgaggac cttcaggctg caaacgggtt aatcaagaat 720
ttgggtcaagg aggaacaaga aaaatcggag aagggtgtcca agagggtcag tgcggtggag 780
gaagtgcgaa gccatgtgaa ggtgctgcag gagatgctga gcatgtaccg caggccaggg 840
caggccccgc ccgaccagga ggccctgcag gtcgtgtatg agagggtgtga aaagctgcgg 900
cccacgtgt tccggttggc gagtgacacc actgatgacg atgatgcact cgcggaaatt 960
ctccaggcaa atgacctct caccacagga gttctgctgt acaaacagggt gatggagggc 1020
cgggtcacct ttggaaacag agtgaccagc tcattgggag acatccctgt ctccagagtc 1080
tttcagaatc cagcaggctg catgaagacc tgccccctga ttgacttggg ggtggacaat 1140
ggacctgcgc agatggggac tgtgggtgcc tctttgcttc atcaggacct ggcagccttg 1200
ggaatcagtg atgctcctgt tacaggcatg gtttctggtc agaattgctg tgaggaaaag 1260
aggaatccct cctccagcac gctgccaggc ggtgggtgttc agaacccttc tgcagacagg 1320
aatttgctgg acctcctctc agcacagcca gctccgtgcc ctctgaatta tgtttcgcag 1380

```


WO 00/12703

PCT/US99/19616

```

aaaagtgtcc ccaaggaagt gccaccaggt actaagtcct ctccagggtg gtccctgggag 1440
gctggccccgt tggctccttc cccatcttca cagaatacac ctctgggtca agtggtttgtc 1500
cctttggagt ctgttaagcc cagcagcctg ccgcctctca ttgtgtatga ccggaatgga 1560
ttcagaattc tgctccactt ctcccagacg ggagcccctg ggcacccaga ggtacagggtg 1620
ctgctcttga ccatgatgag cacggctccc cagcctgtct gggatatcat gtttcaagtg 1680
gctgtgccaa agtcaatgag agtgaagctg cagccggcat ccagctccaa gcttcctgca 1740
ttcagtcctt tgatgcctcc agctgtgata tctcagatgc tgctgcttga caatccacac 1800
aaagaacctt tccgcttacg gtacaagctg acattcaacc aagggtggaca gcctttcagc 1860
gaagtaggag aagtgaaaga cttcccagac ctggcgtgtc tgggcgcgagc ctaacttttc 1920
acaagatgga cccttcattt caagcttagg ctggcggtac ttttgctgtc tagtcaggac 1980
taatcacggg gtttcagtgc ggagtgccaa gagtcctatc ctgacgtcag gctctgggtg 2040
tcaacctctg acttattctg cagatgctct gtgtgtgtgt gtgtgtgtgt gtgtgtgtgt 2100
gtgtgtgtgt gtgtgtgtgt gtgttcgggg agaggggtgg agcacagggc ttgggatatc 2160
ggcagtgtgg gaaatgcgaa gtatttctca tcatcatcat ctctgctaca gtcatgtttc 2220
tgcagtgcag cgagcgacac tgctcctgcc tcaggttgga ggttttatca gccaaagtgt 2280
ttttttcatg tategttcgt tccattcacc cactctgtgc cttgtcagcc tttgaaaggc 2340
ttggttgctc ccaggctgct gttctcaggg accttaaaag ggacctggtt agtcttgggg 2400
cagagagtat ctacttgggc actctcttcc aagaaagacc ttgtctccat tttcattaga 2460
caatgcttct tgtgtgtgtt ctggaagatc ttctaaatgg aatgcttggt gcactgttcc 2520
caggcgagtg gctgccatga gacctgagga ccacacttgg gggaccaatc atgtccttca 2580
ccactgtgcc ttagaatcgc ccttgagacg agttcctggg cagaggggaa agcagctccc 2640
aggccttact caggcctcag gtccatgggt tgggcagcca gtctgggccc ttctcaggat 2700
cctcatctcc atcctcatcc tcttccttca cagcatttac ttggagctct ttgtgacaca 2760
ccatgtcagt catgatgaat cggccaacag ccagccctg ccagctgacg tcacagtcta 2820
agatgggaaa ctgtggtaca gatagacatg aagagagctt agcagtgatt gaggtggtga 2880
ctaaatatac agtcattgaa taaataccat gtagcaagtg tactttgtgg agtgttgagt 2940
aagtggaaaa tggaaagcca gttgcattta gagatgatag gcctaaaggg aactgtcttc 3000
tgtcgagaag taaaggaaac ttcataaagg atgtagaagc ttagctgcct cagagaagag 3060
agaacctgaa gatctgaggg aagctggaca ggagaggtgg atatttgttg atggaagaat 3120
tcaagtttat aatcaattcc cacttagcac ctactgtgtg ctaggaactt gaatgtgtat 3180
gtttgacaag tcctgcttgg cctgatgggt gggagaagga acctgagcct ggctgagatg 3240
gctaggcgga gggctttgaa gtccaagcag ctgaactggc tgggtgggtt tctacctttg 3300
aaactgcaag acttgtttgg agctcttaac tacaatatct gatattttta cagtctgac 3360
ttttgacttc tacatatagt ggaaatctgc caatactaat tgggtggagat gggaaactgta 3420
aaagatcaag tatgctaatt ttaagcaaat gtaaaaactc aataa 3465

```

<210> 13

<211> 2528

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1856357CB1

<400> 13

```

gctcgtggt ggcggaccgg gaggtgctg cggcgccggg gctccgtggc ctggattgaa 60
tccgatcggg agccatgagc gtggacaaag ctgagctatg cgggtctctg ctcacctgg 120
tacagacggt ccacgttcgg tctcctgtg ccagccctca ggacctgagc agcggccttg 180
ccgtagccta tgtgctgaac cagatagacc cctcctgggt caacgaggca tggctccagg 240
gcatctcgga agatccaggc cccaactgga agctgaaggt cagcaatctg aagatgggt 300
tacggagcct agtagagtac tcccaggatg tcctggcgca tcctgtgtca gaagagcatc 360
tcccagatgt gagcctcatt ggagagttct cagacccggc agagctcggc aagctgcttc 420
agctgggtgct gggctgtgcc atcagttgcg agaaaaagca ggaccacatc cagagaatca 480
tgacgctgga agaatcgggt cagcatgtgg tgatggaagc catccaagag ctcatgacca 540
aagacactcc tgactcctg tcaccagaga cgtatggcaa ctttgacagc cagtcccgc 600

```


WO 00/12703

PCT/US99/19616

```

ggtactatatt cctaagtgag gaggetgagg aggggggacga attacagcag cgctgtcttg 660
atctggagcg gcagctgatg ctctgtcag aggagaagca ggcctggcg caagagaatg 720
cagggctgcg ggagcggatg ggccggcctg aaggcgaggg taccaggt ctactgcc 780
agaagctgct gctgctgcaa tcccagctgg agcagttgca ggaggagaac ttcaggctgg 840
agagtggcag ggaggatgag cgctgctgct gtgccgagct ggagaggag gttgcggagc 900
tgcagcaccg gaaccaggcg ctgactagcc tggcccagga ggcacaggcc ctgaaggatg 960
agatggatga actacggcag tcttcggagc gtgctgggca gctggaggcc acgctgacca 1020
gttgccggcg ccgcttgggc gagctgaggg agctgcggcg gcaggtgcgg cagctggagg 1080
aacgcaacgc cggccacgcc gagcgacgc gacaactgga ggatgagcta cgccgagcgg 1140
gctccctgcg cggccagctg gagggcgagc ggccggcaggt gcaggaactg cagggccagc 1200
ggcaggagga ggccatgaag gccgagaaat ggctatattga atgccgcaac ctggaggaaa 1260
agtatgagtc ggtgacaaag gagaaggagc ggctgttggc ggagcgggac tccttgcggg 1320
aggccaatga ggagctgcgc tgcgcccagc tgcagccgcg ggggttgacc caggccgatc 1380
cctcactgga tcccacctcc acaccgtgg ataacttagc cgagagatc ctgcctgcgg 1440
agctcaggga gacgctcctg cggcttcagc tggagaacaa gcggctgtgc aggcaggagg 1500
cggccgaccg ggagcggcag gaggagctgc agcgccacct ggaggatgcc aaccgcgcgc 1560
gccacgggtt ggagacgcag caccggctga accagcagca gctatccgag ctgcggggcc 1620
aggtggagga cctgcagaaa gccctgcagg agcagggggg caagactgaa gatgccattt 1680
ccattttgct gaaaaggaag ctggaggaa atttgcagaa gcttcatgag gcagatctgg 1740
agttgcagag gaagcgggag tacattgagg agctggagcc accactgac agcagcacag 1800
cccggcggat cgaggagctg cagcataact tgcagaagaa ggacgcggac ttgcgggcca 1860
tggaggagcg ataccgccc tacgtggaca agcccgcag ggtcatgcag accatggaac 1920
ccaagcagcg gccagctgcg ggggcacctc cagaactcca ttccctgagg acacagctcc 1980
gagaacggga tgtccgcatc cgacacctg agatggactt tgagaaaagc cgaagtcagc 2040
gggagcagga agaaaagctg ctcatcagtg cctggtataa tatgggcatg gccttgcagc 2100
agcgagctgg ggaggagcgg gcgcctgcc atgcccagtc attcctggca cagcagcggc 2160
tggcaaccaa ttctcgccgt ggacccttgg gacgcctggc atctctgaac cttcgcccc 2220
ctgacaagca ctgacagacc tcacaatcaa gccagcctgg gctccacca ccctggcttc 2280
ctccagctca catggcgccc agcactgggc ttcagccagg tgctcgagag ctttgaggcc 2340
atgatctctg ctcttccctc tcccagattg gtggggaggg agggcgagg gtagatatag 2400
gcctgttctt tttagcaatg tgattcttgt tgttgattct ctctctggag ttcattgtgt 2460
gcctcaggag actctgattt tatatttgag aaaaataaag gcgttcaatc tgcaaaaaaa 2520
aaaaaaaaa 2528

```

<210> 14

<211> 671

<212> DNA

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No:1871275CB1

<400> 14

```

gagagatata tggaaggaag ggaagtaagc agtcacagac gctggcggcc accagaagtt 60
tgagcctctt tggtagcagg aggetggaag aaaggacaga agtagctctg gctgtgatgg 120
ggatcttact gggcctgcta ctctggggc acctaacagt ggacacttat ggccgtccca 180
tcctggaagt gccagagagt gtaacaggac cttggaaagg ggatgtgaat ctccctgca 240
cctatgaccc cctgcaaggc tacaccaag tcttggtgaa gtggctggta caacgtggct 300
cagaccctgt caccatcttt ctacgtgact cttctggaga ccatatccag caggcaaagt 360
accagggccg cctgcatgtg agccacaagg ttccaggaga tgtatccctc caattgagca 420
ccctggagat ggatgaccgg agccactaca cgtgtgaagt cacctggcag actcctgatg 480
gcaaccaagt cgtgagagat aagattactg agctccgtgt ccagaaacac tcctcaaagc 540
tactcaagac caagactgag gcacctacaa ccatgacata ccccttgaaa gcaacatcta 600
cagtgaagca gtccctgggac tggaccactg acatggatgg ctagcttgga gagaccagtg 660
ctggggcagg a 671

```


WO 00/12703

PCT/US99/19616

<210> 15
 <211> 1146
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No:2645806CB1

<400> 15
 tacttccggg agagaatggg aggggtggaaa attttgtgcg tttggcgggt ttcgctctct 60
 tcataagtat tgatcattcc gcagccctgc ggaccggaca cgtgaggagg tagtgacgcc 120
 gacactgcc aacacactg ctacaaggct ccagatggcc acgtctctgg attttaaaac 180
 ttatgtagat caggcatgta gagctgctga ggagtttgtc aatatttact atgagacaat 240
 ggataaaaga agacgggcac taaccaggct gtatctggac aaggccacct taatatggaa 300
 tggaaatgct gtttcagggc tggatgccct aaataatttt tttgacacat tgccttctag 360
 tgagttccag gtcaatatgt tagattgcca accagttcat gagcaagcaa ctcagtccca 420
 aactacagtt cttgttgtga ccagtggaaac tgtgaagttt gatggaaaca aacaacattt 480
 cttcaaccag aacttcctgc tgactgctca gtccactccc aacaatactg tgtggaagat 540
 tgcaagtgat tgcttccggt ttcaagattg gtctagtagt taaaggggca aaagtccatt 600
 ctcatattgg ccattagttc cagcaattga aatttatgtg aattattttg attgtagaag 660
 cactataata tgtgctgaaa ctaaatttct ttaatatatt ctattcctgt cagcaccttt 720
 tctagcagct gccagtttgg agcattgccc tctaagagct ttaaaactat ttttttacat 780
 gccttatata cattccacta atgacattct tataataata ttaaacacat gatcttggta 840
 ctaacatact cactgtgaac ccagcctatt gcaaaaataa aatcttttta taatattatc 900
 tatgggatgt cagcacaata taacactctg ggaagaagtg gagttttttg gttattaggt 960
 taatttttcta gtaaaacacg ttgcctgttt tcagttaaca ctggtaatgc cattttaata 1020
 tatggctttt tcaaatcagt tcagtgaaaa tagtacagat ttaggtttac ataactactc 1080
 tgacatactg gaattgcata tagagatggt cagtggtcgt ttttcatttt aagtaatttt 1140
 tgtttt 1146

<210> 16
 <211> 1175
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No:3437773CB1

<400> 16
 gttacctatt ggtttgtttc tgcctatgtc tgtttctctc cctctaactg tgatgggttag 60
 agagagagat tggattggaa tccatctttt ttcctgtat ctttctctcc ctgtgggtat 120
 ccctgatttt ggctccatct ggtcagactt cctcttcaaa ttcttggtga ttggcagtgc 180
 aggaactggc aaatcatgtc tccttcatca gttcattgag aataagttca aacaggactc 240
 caaccacaca atcggcgtgg agtttggatc ccgggtgggc aacgtgggtg ggaagactgt 300
 gaagctacag atttgggaca cggctggcca ggagcgggtt cggtcagtga cgcggagtta 360
 ttaccgaggg gcggctggag ccctgctggt gtacgacatc accagccggg agacatacaa 420
 ctactggct gcctggctga cggatgcccg caccctggcc agccccaaca tcgtggtcat 480
 cctctgtggc aacaagaagg acctggaccc tgagcgggag gtcactttcc tggaggcctc 540
 ccgctttgcc caggagaatg agctgatgtt cctggagacc agcgtctca caggcgagaa 600
 cgtggaggag gcgttcctca agtgtgcccg cactatcctc aacaagattg actcaggcga 660
 gctagaccgc gagaggatgg gctctggcat tcagtacggg gatgcgtccc tccgccagct 720
 tcggcagcct cggagtgcc aggcctgggc ccctcagccg tgtggctgct gagctctgtg 780
 gagccagctc acctgttctc caggaccagc cctgctgggg cccaggccca ggctctgaga 840

WO 00/12703

PCT/US99/19616

```
ggcctgtcc taacctgcc tggccccgga gaagctacgt tgccacctgt ccccttccc 900
tggcctggtg gggcctggct ttggggcaag actgagccac gggggaaggg ggaatcccgt 960
acctgctgct gcttcctctg tcttggctaa cgtctgtccc cctgaacccc taaccatc 1020
ccaagagctc ccaaagcctg agaccagggt catttgtccc caactcecca tctggccctg 1080
ctgttgctag tacctgttat ttattacctg gaggcctgtc cagcaccac cctaccccca 1140
taaagcattg ttacacctg taacacacac aaaaaa 1175
```


WO 00/12703

PCT/US99/19616

What is claimed is:

1. A substantially purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, and SEQ ID NO:8, and fragments thereof.
2. A substantially purified variant having at least 90% amino acid identity to the amino acid sequence of claim 1.
3. An isolated and purified polynucleotide encoding the polypeptide of claim 1.
4. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 3.
5. An isolated and purified polynucleotide which hybridizes under stringent conditions to the polynucleotide of claim 3.
6. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 3.
7. A method for detecting a polynucleotide, the method comprising the steps of:
 - (a) hybridizing the polynucleotide of claim 6 to at least one nucleic acid in a sample, thereby forming a hybridization complex; and
 - (b) detecting the hybridization complex, wherein the presence of the hybridization complex correlates with the presence of the polynucleotide in the sample.
8. The method of claim 7 further comprising amplifying the polynucleotide prior to hybridization.
9. An isolated and purified polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO:9-16, and fragments thereof.
10. An isolated and purified polynucleotide variant having at least 90% polynucleotide sequence identity to the polynucleotide of claim 9.
11. An isolated and purified polynucleotide having a sequence which is complementary to the polynucleotide of claim 9.
12. An expression vector comprising at least a fragment of the polynucleotide of claim 3.
13. A host cell comprising the expression vector of claim 12.
14. A method for producing a polypeptide, the method comprising the steps of:
 - a) culturing the host cell of claim 13 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.

WO 00/12703

PCT/US99/19616

15. A pharmaceutical composition comprising the polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.
16. A purified antibody which specifically binds to the polypeptide of claim 1.
17. A purified agonist of the polypeptide of claim 1.
- 5 18. A purified antagonist of the polypeptide of claim 1.
19. A method for treating or preventing a disorder associated with decreased expression or activity of PTAM, the method comprising administering to a subject in need of such treatment an effective amount of the pharmaceutical composition of claim 15.
- 10 20. A method for treating or preventing a disorder associated with increased expression or activity of PTAM, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 18.